Statins: a repurposed drug to fight cancer

Wen Jiang¹†, Jin‑Wei Hu¹†, Xu‑Ran He², Wei‑Lin Jin³* and Xin‑Yang He⁴*

Abstract
As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anti-cancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins.

Keywords: Drug repurposing, Mevalonate pathway, Statins, Synergistic antitumor, Tumor microenvironment

Background
Currently, cancer remains the leading cause of death in every country in the world, and the burden of cancer morbidity and mortality is growing rapidly worldwide [1]. The global cancer burden in 2040 is expected to be 28.4 million cases, representing an increase of 47% over 2020 [1]. The development of new drugs to improve cancer treatment can take many years and is extremely expensive [2]. One way to reduce this time-frame and cost is to repurpose existing drugs that show potential cytotoxic activity. Drug repurposing has been used in cancer treatment for many years. Although these drugs have an alternative original indication, they are now being widely used in cancer treatment [3].

Statins are powerful competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase (HMGCR) and are commonly used as lipid-lowering drugs. The source of human plasma cholesterol is either dietary intake or de novo biosynthesis by cells. Statins reduce plasma cholesterol levels by reducing de novo cholesterol biosynthesis and inducing changes in low-density lipoprotein (LDL) receptor expression. However, in the past, studies have shown that statins exhibit pleiotropic effects independent of their lipid-lowering properties. It has been reported that the epigenetic effects of statins mediate these pleiotropic effects, at least to some extent [4]. Among them, the anti-tumor properties of statins have attracted particular attention. For example, Kodach et al. found that statins act as DNA methyltransferase (DNMT) inhibitors, demethylating the bone morphogenetic protein 2 (BMP2) promoter, activating BMP signaling, inducing differentiation of colorectal cancer (CRC) cells, and reducing “stemness” [5]. As repurposed drugs, statins are being investigated...
for both the prevention and treatment of cancer. Therefore, the anticancer mechanisms of statins have attracted a lot of attention. Among them, the most widely studied is the mevalonate pathway. The flux of the mevalonate pathway is an absolute requirement for all cells, including cancer cells. YAP and TAZ are master transcriptional regulators of normal organ growth and tumor growth [6]. Studies have revealed that the mevalonate pathway promotes YAP/TAZ nuclear localization and activity, while statins impair the YAP/TAZ-dependent transcriptional responses by blocking the mevalonate pathway, thereby inhibiting the development of cancer cells [7]. In addition to the mevalonate pathway, a variety of other anticancer mechanisms of statins have been uncovered one after another.

The development of statins as “cholesterol-lowering” drugs began in the mid-1970s. Simvastatin, lovastatin, and pravastatin are all fungal-derived compounds with very similar structures, although the additional hydroxyl groups make pravastatin more hydrophilic than simvastatin or lovastatin. In contrast, fluvastatin, pitavastatin, cerivastatin, atorvastatin, and rosuvastatin are synthetic derivative compounds with similarities in structure, such as common fluoride side groups (Fig. 1). Statins may have different intracellular effects depending on their chemical structure [8]. Compared with hydrophilic statins (such as pravastatin and rosuvastatin), lipophilic statins (such as simvastatin) show a greater ability to penetrate the cell membrane and enter hepatocytes and non-hepatocytes through passive diffusion [9, 10]. Furthermore, lipophilic statins have higher pro-apoptotic activity than hydrophilic statins [11]. Due to their higher cytotoxic potential, lipophilic statins may be beneficial in cancer treatment [12].

Here, we review the anti-cancer mechanisms of statins as well as the new perspectives and unique significance of statins in adjuvant cancer therapy to provide a reference for future clinical trials and applications of statins.

**Conventional and off-label of statins**

Statins were initially developed to lower lipids and prevent cardiovascular disease. Statins act as competitive inhibitors of HMGCR and can prevent cardiovascular diseases such as atherosclerosis by reducing cholesterol synthesis [13–15]. The effect of statins on cardiovascular morbidity and mortality in patients with and without atherosclerotic disease has been well proven. Furthermore, statins appear to exert pleiotropic effects independent of their lipid-lowering properties, including effects on diabetes, neurological diseases, coronary heart disease, inflammation and cancer [16]. Given the anticancer effects of statins, and the fact that statins are

---

**Fig. 1** Chemical structures of selected statins
well-tolerated, inexpensive, and less toxic than conventional chemotherapy drugs, many researchers considered repurposing statins as a promising strategy for the treatment of cancer.

**Anti-tumor effects of statins**

The anti-cancer properties of statins have attracted considerable interest in recent decades [17]. A growing number of population-based studies and interventional clinical trials indicate that statins produce a series of positive anti-cancer effects (Tables 1 and 2) [56–60].

**Population-based studies**

In recent years, a large number of population-based observational studies on the anti-tumor effects of statins have been carried out successively (Table 1); most such studies indicate that statins prolong survival and improve prognosis in cancer patients. A 15-year large-scale observational study of a Danish subgroup showed that the use of statins in cancer patients was associated with a reduction in cancer-related mortality (including 13 cancers) compared with patients who did not use statins [61]. Another retrospective study conducted on 146,326 menopausal women in 40 clinical centers in the USA, with an average follow-up time of 14.6 years, showed that people who currently use statins have a significantly lower risk of cancer death (hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.71–0.86) and all-cause mortality (HR, 0.80; 95% CI, 0.74–0.88) compared with people who have never used statins [57]. A meta-analysis of 1,111,407 cancer patients showed that the use of statins reduced all-cause mortality and cancer-specific mortality by 30% and 40%, respectively [58]. Recently, a study involving 303 patients with advanced pancreatic cancer showed that the use of statins (simvastatin and atorvastatin) was associated with increased overall survival in patients [62]. In addition, in patients receiving radiotherapy, surgery and chemotherapy for advanced pancreatic cancer, statin treatment was associated with a 2-year increase in survival, suggesting that statins help improve the outcome of interventions for advanced pancreatic cancer [63]. A meta-analysis of breast cancer studies showed that the overall use of statins was associated with lower cancer-specific and all-cause mortality. Furthermore, while lipophilic statins were found to be associated with lower breast cancer-specific and all-cause mortality, the protective effect of hydrophilic statins on these outcomes was weak, suggesting that the protective effects of statins on breast cancer are affected by the type of statin [64]. However, in another meta-analysis of 7,858 breast cancer cases, no association between statin use and breast cancer risk was observed at a mean follow-up of approximately 5 years [relative risk (RR), 1.02; 95% CI, 0.89–1.18] [65]. Given that this conclusion is limited by the relatively short follow-up time of the studies analyzed, further studies are required to investigate the effect of long-term statin use on breast cancer risk. In prostate cancer, a study conducted in 4,204 men who underwent prostate biopsy suggested that people who used statins had a significantly reduced risk (8%) of prostate cancer compared with people who did not use statins (RR, 0.92; 95% CI, 0.85–0.98) [22]. Another analysis of 1,001 prostate cancer patients (289 statin users) reported a 0.19 hazard ratio for prostate cancer-specific death among statin users compared with men who did not use statins (95% CI, 0.06–0.56) [66]. A recent clinical study showed that statin use is associated with a reduced risk of phosphatase and tenasin homolog (PTEN)-negative and fatal prostate cancer [23]. However, the results of a population-based epidemiologic study showed that the use of statins was not associated with overall prostate cancer risk [67], although the credibility of the results of the study are open to question due to the relatively small sample size and the existence of potential selection and recall biases. In gastric cancer, a recent nationwide cohort study suggested that the use of statins is related to a decrease in gastric cancer mortality in the general population, but has no correlation with the incidence of gastric cancer [30]. A recent prospective observational study of ovarian cancer patients conducted in Australia suggested that the increase in patient survival is related to the use of lipophilic statins, but not to hydrophilic statins [59]. In a large-scale population study of 4,913 patients with diffuse large B-cell lymphoma, statins improved the survival rate in a dose-dependent manner [39]. A study of 999 colon cancer patients showed that the use of statins after diagnosis was significantly associated with a lower risk of death from any cause (adjusted RR, 0.67; 95% CI, 0.51–0.87) and a lower risk of cancer death (adjusted RR, 0.66; 95% CI, 0.49–0.89) [31]. Similarly, a recent meta-analysis showed that statin use was significantly associated with a decrease in overall mortality and cancer-specific mortality of CRC [32]. In liver cancer, a meta-analysis involving 59,073 patients showed that statin use was significantly associated with a reduced risk of hepatocellular carcinoma (HCC) progression compared with those who did not use statins (RR, 0.54; 95% CI: 0.47–0.61) [68].

Inconsistencies in observational studies regarding statin use and cancer morbidity and mortality may be due to significant differences in follow-up periods and potential shortcomings in retrospective and observational studies. For example, statin users might be more health-conscious and might see their doctor more frequently than non-users, so non-users are more likely to be diagnosed with cancer at a later stage compared with statin users. In addition, the race diversity of the population in studies
| Cancer          | Statins                                                                 | Combination agent | Population | Findings                                                                                                                                                                                                 | Ref. |
|-----------------|--------------------------------------------------------------------------|-------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Breast cancers  | NR (Before the diagnosis)                                                | NR                | 7452       | The use of statins was associated with increased overall mortality only in patients with ER-positive breast cancer                                                                                      | [18] |
|                 | NR (After the diagnosis)                                                 | NR                | 17,880     | Statin use after a diagnosis of breast cancer had reduced mortality due to breast cancer and all causes                                                                                                   | [19] |
|                 | Lipophilic statins and hydrophilic statin                                | NR                | 18,769     | Simvastatin was associated with a reduced risk of breast cancer recurrence among Danish women diagnosed with stage I–III breast carcinoma                                                               | [20] |
|                 | Lipophilic statins (After the diagnosis)                                 | NR                | 1945       | The use of lipophilic statins was associated with a reduced risk of breast cancer recurrence                                                                                                             | [21] |
| Prostate cancer | NR (Before the diagnosis)                                                | NR                | 1022       | The use of statins was associated with a decreased risk of prostate cancer                                                                                                                             | [22] |
|                 | Atorvastatin, simvastatin, fluvastatin, pravastatin and rosvastatin     | NR                | 44,126     | The use of statins is associated with lower risk of PTEN-null and lethal prostate cancer                                                                                                               | [23] |
|                 | Simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin and rosvastatin | NR                | 42,480     | The use of statins was associated with a risk reduction overall (6%) and, specifically with advanced PCa (10%)                                                                                         | [24] |
|                 | NR                                                                       | NR                | 1367       | The use of statins was not associated with the risk of advanced prostate cancer                                                                                                                          | [25] |
|                 | NR                                                                       | NR                | 1940       | The use of statins was associated with the increased risk of prostate cancer                                                                                                                             | [26] |
| Pancreatic cancer| Atorvastatin, rosvastatin, simvastatin, lovastatin and pravastatin      | Gemcitabine/paclitaxel | 797        | The use of statins was associated with better survival in metastatic pancreatic cancer patients who were treated with first-line chemotherapy                                                             | [27] |
|                 | Atorvastatin, rosvastatin, simvastatin, lovastatin and pravastatin      | NR                | 2142       | The use of statins was associated with lower mortality risk in patients with pancreatic cancer                                                                                                         | [28] |
| Gastric cancer  | NR                                                                       | NR                | 1835       | Statin use may dose-dependently improve the OS of patients with GC after surgery and adjuvant chemotherapy                                                                                              | [29] |
|                 | NR                                                                       | NR                | 80,271     | The use of statins was associated with a reduction of gastric cancer mortality in the general population but not with gastric cancer incidence                                                                 | [30] |
| Colorectal cancer| NR (After the diagnosis)                                                 | NR                | 999        | The use of statins was associated with reduced risk of death from any cause or from cancer                                                                                                               | [31] |
|                 | NR                                                                       | NR                | 387,518    | The use of statins was significantly associated with a decrease in overall mortality and cancer-specific mortality of CRC                                                                                   | [32] |
| Ovarian cancer  | NR (After the diagnosis)                                                 | NR                | 4419       | The use of statins was not significantly associated with the reduction of mortality in patients with ovarian cancer                                                                                       | [33] |
|                 | Simvastatin, fluvastatin, atorvastatin, pravastatin and rosvastatin     | NR                | 1255       | The use of statins was associated with a reduced risk of overall mortality                                                                                                                             | [34] |
### Table 1 (continued)

| Cancer                          | Statins                                                                 | Combination agent | Population | Findings                                                                                                                                                                                                 | Ref. |
|---------------------------------|-------------------------------------------------------------------------|-------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Lung cancer                     | Simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin and rosvastatin (After the diagnosis) | EGFR-TKIs         | 1707       | Statins enhance the therapeutic effect and increase survival in patients with lung cancer receiving EGFR-TKI therapy                                                                                     | [35] |
|                                 | NR (Before and after the diagnosis)                                      | NR                | 3638       | The use of statins (particularly simvastatin) was associated with reduced cancer-specific mortality in patients with lung cancer                                                                          | [36] |
|                                 | Atorvastatin, simvastatin, lovastatin, pravastatin, and rosvastatin (Before and after the diagnosis) | NR                | 19,974     | The use of statins was associated with decreased mortality risk in patients with lung cancer                                                                                                             | [37] |
| Lymphoma                        | Lovastatin, pravastatin, rosvastatin, fluvastatin, simvastatin, and atorvastatin (Before the diagnosis) | NR                | 18,657     | The use of statins was associated with a lower risk of NHL                                                                                                                                           | [38] |
|                                 | NR (Before the chemo-immunotherapy)                                      | NR                | 4913       | The use of statins was associated with the improved survival in newly diagnosed diffuse large B-cell lymphoma                                                                                          | [39] |
| Glioblastoma                    | NR                                                                      | NR                | 1093       | The use of statins was unrelated to OS or PFS of GBM patients                                                                                                                                     | [40] |
|                                 | NR                                                                      | NR                | 2469       | The use of statins was not associated with the risk of GBM                                                                                                                                             | [41] |
|                                 | NR (Before the diagnosis)                                               | NR                | 280,465    | The use of statins was associated with the increased risk of GBM                                                                                                                                   | [42] |
| Endometrial cancer              | NR                                                                      | NR                | 77,509     | The use of statins was not associated with the risk of endometrial cancer                                                                                                                             | [43] |
| Kidney cancer                   | NR                                                                      | NR                | 18,105     | Statin use among patients with kidney cancer is associated with significantly improved cancer-specific and overall survival                                                                            | [44] |
| Multiple myeloma                | NR (Before or after the diagnosis)                                       | NR                | 4957       | The use of statin was associated with a reduced risk of both all-cause and MM-specific mortality                                                                                                       | [45] |
| Head and neck squamous cell carcinoma | NR (After the diagnosis)                                           | NR                | 1194       | Statin use at the time of diagnosis of HPV-negative squamous cell carcinoma (SCC) of the larynx, hypopharynx, and nasopharynx demonstrated improved OS and DSS                                                 | [46] |

**Abbreviations:** CRC Colorectal cancer, DDS Disease-specific survival, EGFR-TKIs Epidermal growth factor receptor tyrosine kinase inhibitor, GBM Glioblastoma multiforme, GC Gastric cancer, MM Multiple myeloma, NHL Non-Hodgkin lymphoma, NR Not reported, OS Overall survival, PCa Prostate cancer, PFS Progression-free survival
Table 2  Statin use in interventional clinical anticancer studies

| Cancer                | Statins                          | Combination agent  | Population | Findings                                                                 | Ref/CTG.ID          |
|-----------------------|----------------------------------|--------------------|------------|--------------------------------------------------------------------------|---------------------|
| Breast cancer         | Fluvastatin (After the diagnosis)| NR                 | 40         | Fluvastatin decreased breast tumor proliferation and increased apoptosis  | [47]                |
|                       | Atorvastatin (After the diagnosis)| NR                 | 42         | Atorvastatin decreased breast cancer proliferation by influencing the expression of cyclin D1 and p27 | [48]                |
|                       | Simvastatin (After the diagnosis)| FAC                | 60         | Simvastatin may improve the efficacy of FAC in LABC patients             | [49]                |
|                       | Simvastatin (After the diagnosis)| NR                 | 50         | NR                                                                       |                     |
| Prostate cancer       | Fluvastatin (After the diagnosis)| NR                 | 33         | Fluvastatin is associated with promising effects on tumor cell apoptosis  | [50]                |
|                       | Atorvastatin (After the diagnosis)| ADT                | 400        | NR                                                                       |                     |
| Gastric cancer        | Simvastatin (After the diagnosis)| Cisplatin/Capecitabine | 244   | Adding simvastatin to capecitabine–cisplatin did not increase PFS in patients with gastric cancer | [51]                |
|                       | Pravastatin (After the diagnosis)| ECC                | 30         | Adding pravastatin to ECC did not improve outcome in patients with advanced gastric cancer | [52]                |
| Lung cancer           | Simvastatin (After the diagnosis)| Gefitinib          | 106        | Simvastatin may improve the efficacy of gefitinib in that subgroup of gefitinib-resistant NSCLC patients | [53]                |
|                       | Simvastatin (After the diagnosis)| Irinotecan/Cisplatin | 62       | NR                                                                       | NCT00452634         |
| Liver cancer          | Pravastatin (After the diagnosis)| Sorafenib           | 312        | Adding pravastatin to sorafenib did not improve survival in patients with advanced HCC | [54]                |
|                       | Atorvastatin (After the diagnosis)| NR                 | 240        | NR                                                                       | NCT03024684         |
|                       | Pravastatin (After the diagnosis)| TAE/S-FU            | 83         | Pravastatin prolonged the survival of patients with advanced HCC         | [55]                |
| Colorectal cancer     | Simvastatin (After the diagnosis)| Cetuximab/Irinotecan | 52        | NR                                                                       | NCT01281761         |
| Pancreatic cancer     | Simvastatin (After the diagnosis)| Gemcitabine         | 106        | NR                                                                       | NCT00944463         |
| Ovarian cancer        | Simvastatin (After the diagnosis)| NR                 | 20         | NR                                                                       | NCT04457089         |
| Glioblastoma          | Atorvastatin (After the diagnosis)| Radiotherapy/Temozolomide | 36   | NR                                                                       | NCT02029573         |
| Endometrial cancer    | Rosuvastatin (After the diagnosis)| Megestrol acetate  | 43         | NR                                                                       | NCT04491643         |
| Kidney cancer         | Atorvastatin (After the diagnosis)| Zoledronate         | 11         | NR                                                                       | NCT00490698         |
| Head and neck cancer  | Atorvastatin (After the diagnosis)| NR                 | 414        | NR                                                                       | NCT04915183         |

Abbreviations: ADT Androgen deprivation therapy, CRC Colorectal cancer, DDS Disease-specific survival, ECC Epirubicin, cisplatin and capecitabine, EGFR-TKIs Epidermal growth factor receptor-tyrosine kinase inhibitor, FAC fluorouracil, adriamycin and cyclophosphamide, GBM Glioblastoma multiforme, GC Gastric cancer, HCC Hepatocellular carcinoma, LABC Locally advanced breast cancer, MM Multiple myeloma, NHL Non-Hodgkin lymphoma, NR Not reported, NSCLC Non-small cell lung cancer, OS Overall survival, PCa Prostate cancer, PFS Progression-free survival, TAE Transcatheter arterial embolization, 5-FU 5-fluorouracil
could be limited. Therefore, it is difficult to determine causality from observational studies. Inconsistent findings highlight the importance of well-designed clinical trials to accurately determine the potential of statins as single- or combination-therapy anticancer drugs.

**Interventional clinical trials**

In addition to population-based studies, the ability of statins to kill tumors has also been investigated in several interventional clinical trials (Table 2). A perioperative trial showed that high-dose (80 mg/day) neoadjuvant fluvastatin decreased breast tumor proliferation and increased apoptosis compared with low-dose (20 mg/day) treatment [47]. Similarly, another clinical trial in breast cancer patients treated with a high dose of atorvastatin (80 mg/day) in the first 2 weeks before surgery suggested that this treatment decreased breast cancer proliferation by influencing the expression of cyclin D1 and p27 [48]. Recently, Longo et al. revealed that neoadjuvant fluvastatin treatment prior to radical prostatectomy may be effective in inducing intratumoral apoptosis in patients with localized prostate cancer [50].

Statins have also been shown to exert antitumor effects by enhancing the response of combination therapy. Recently, Yulian et al. found that simvastatin combined with FAC (Fluorouracil, adriamycin and cyclophosphamide) improved the response to neoadjuvant chemotherapy in patients with advanced local breast cancer [49]. Cantini et al. found that high-intensity statins enhanced the clinical activity of programmed death receptor-1 (PD-1) inhibitors in patients with malignant pleural mesothelioma and advanced non-small cell lung cancer [69]. Han et al. found that simvastatin may improve the efficacy of gefitinib in gefitinib-resistant non-small cell lung cancer (NSCLC) patients [53]. Kawata et al. reported that pravastatin prolonged survival in patients with advanced HCC who received 5-fluorouracil (5-FU) treatment after transcatheter arterial embolization (TAE) [55]. However, Jouve et al. found that adding pravastatin to sorafenib did not improve survival in patients with advanced HCC [54]. Similarly, Kim et al. found that adding simvastatin to capecitabine–cisplatin did not increase PFS in patients with gastric cancer [51]. Konings et al. also found that adding pravastatin to ECC (epirubicin, cisplatin and capecitabine) did not improve outcome in patients with advanced gastric cancer [52].

In summary, the anti-cancer properties of statins have been demonstrated in several clinical and epidemiological studies. However, these effects are not consistent and in several clinical studies, statins were not associated with a reduction in cancer mortality and morbidity, with some even suggesting the opposite effect. Therefore, the anti-cancer properties of statins require further exploration of mechanism of action to maximize design of experiments for further validation in clinical trials.

**Anti-cancer mechanisms of statins**

The anticancer properties of statins have been demonstrated in many preclinical and clinical studies. Therefore, the mechanism underlying the anti-cancer effect of statins has aroused widespread interest. The many anti-cancer mechanisms of statins that have been proposed in recent years are summarized in Fig. 2 and Table 3.

**The mevalonate pathway**

Metabolic changes are a hallmark of cancer cells [135]. However, it has always been a challenge to identify drugs that target multiple tumor types and cancer-specific
| Cancer                | Statins         | Type of study | Dose of administration | Combination agent | Findings                                                                                                                                                                                                 |
|----------------------|-----------------|---------------|------------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Breast cancers       | Simvastatin     | In vitro      | 0–1000 μM              | -                 | Simvastatin induces the apoptosis of MCF-7 cells by increasing caspase-3 and Bax expression                                                                                                                     |
|                      | Simvastatin     | In vitro      | 0–150 μM               | -                 | Simvastatin induces apoptosis, suppress proliferation and dephosphorylate sequential signaling cascades of PI3K/Akt/mTOR and MAPK/ERK pathways of breast cancer                                                                 |
|                      | Atorvastatin    | In vitro      | 0–80 μM                | -                 | The anti-proliferative effect of atorvastatin on breast cancer cells is mediated by the induction of both apoptosis and autophagy                                                                                  |
|                      | Simvastatin     | In vitro      | 0–200 μM               | -                 | Simvastatin induces apoptosis via involvement of JNK in breast cancer cells independent of their ER or p53 expression status                                                                                   |
|                      | Lovastatin      | In vitro      | 0–50 μM                | -                 | Lovastatin activates LKB1-AMPK-p38MAPK-p53-survivin cascade to cause MCF-7 cell death                                                                                                                      |
|                      | Simvastatin     | In vitro      | 0–5 μM                 | -                 | Simvastatin increased the expression of miR-140-5p in a dose dependent manner via activating transcription factor NRF1, reduced cell proliferation and induced apoptosis                                                |
|                      | Simvastatin     | In vitro      | 0–10 μM                | -                 | Simvastatin showed the reduction in DNA synthesis and induced cell cycle arrest in the G1 phase in MCF-7 CSCs                                                                                                 |
|                      | Mevastatin      | In vitro and vivo | 0–16 μM (In vitro) 10 mg/Kg (In vivo) | Histone deacetylase inhibitors (HDACi) | Combination treatment inhibited autophagic flux by preventing Vps34/Beclin1 complex formation and downregulating prenylated Rab7                                                                          |
|                      | Simvastatin     | In vitro      | 0–100 μM               | Doxorubicin       | Simvastatin acts synergistically with the anti-cancer drug doxorubicin against MCF-7 cells through a downregulation of the cell cycle or induction of apoptosis                                                    |
|                      | Simvastatin     | In vitro      | 0–100 μM               | Pentoxifylline    | The combined use of pentoxifylline and simvastatin may drive dormant autophagic cancer cells to undergo apoptosis                                                                                         |
|                      | Simvastatin     | In vitro and vivo | 0–10 μM (In vitro) 5 mg/Kg (In vivo) | -                 | Simvastatin induces derepression of PTEN expression via NF-kB to inhibit breast cancer cell growth                                                                                                          |
|                      | Lovastatin      | In vitro      | 0–100 μM               | -                 | Lovastatin treatment down-regulates the expression of Bcl-2 and activates apoptosis through a mitochondria-operated, ErbB2-regulated mechanism                                                             |
| Cancer          | Statins                           | Type of study | Dose of administration | Combination agent | Findings                                                                                                                                                                                                 |
|----------------|-----------------------------------|---------------|------------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Prostate cancer| Simvastatin and fluvastatin       | In vitro      | 0–10 μM                | -                 | Statins decrease cell proliferation and induce cell apoptosis, probably mediated via a downregulation of AKT/FOXO1 phosphorylation in prostate cancer cells [82]                                                   |
|                | Simvastatin                       | In vitro      | 0–50 μM                | Irinotecan        | Combined treatment of simvastatin with irinotecan resulted in enhancement of growth inhibition and induction of prostate cancer cell apoptosis via inhibition of MCL-1 [83]                                         |
|                | Atorvastatin                      | In vitro      | 0–50 μM                | Irradiation       | Atorvastatin enhances the radiosensitivity of hypoxia-induced prostate cancer cells by decreasing the expression of HIF-1α protein [84]                                                               |
|                | Atorvastatin                      | In vitro      | 0–5 μM                 | Caffeine          | The combination of atorvastatin and caffeine suppressed proliferation and induced apoptotic death by downregulating phospho-Akt, phospho-Erk1/2, anti-apoptotic Bcl-2 and Survivin protein levels [85]          |
|                | Simvastatin                       | In vitro and vivo | 0–100 μM (In vitro) 2 mg/kg (In vivo) | -                 | Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression [86]                                |
|                | Atorvastatin, mevastatin, simvastatin and rosuvastatin | In vitro      | 0–10 μM                | Celecoxib         | The combination of atorvastatin and celecoxib more strongly inhibited growth and the activation of Akt, Erk1/2 and NF-κB in cultured LNCaP cells than either agent alone. In addition, administration of a combination of celecoxib and atorvastatin had a strong inhibitory effect on the progression of androgen-dependent LNCaP prostate tumors to androgen independence in castrated severe combined immunodeficient (SCID) mice [87] |
|                | Atorvastatin                      | In vitro      | 0–10 μM                | -                 | Statins reduce the migration and colony formation of PC-3 cells in human bone marrow stroma by inhibiting GGPP production, reducing the formation and the spread of metastatic prostate colonies [88] |
|                | Atorvastatin                      | In vitro      | 0–10 μM                | -                 | Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription [89]                                                                                                    |
|                | Lovastatin and simvastatin        | In vitro      | 0–2 μM                 | -                 | Lovastatin and simvastatin induced apoptosis and cell growth arrest in the G1 phase by inactivating RhoA [90]                                                                                           |
### Table 3 (continued)

| Cancer             | Statins        | Type of study | Dose of administration | Combination agent | Findings                                                                                                                                                                                                 | Ref.  |
|--------------------|----------------|---------------|-------------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Pancreatic cancer  | Pitavastatin   | In vitro and vivo | 0–0.5 μM (In vitro) 5 mg/kg (In vivo) | Gemcitabine       | The combination of gemcitabine and pitavastatin synergically suppressed the proliferation of MIA PaCa-2 cells through causing sub-G1 and S phase cell cycle arrest, activated autophagy and effectively inhibited tumor growth in a nude mouse mode of Mia PaCa-2 xenografts | [91] |
| Gastric cancer     | Simvastatin    | In vitro      | 0–100 μM                | -                 | Simvastatin inhibited the proliferation and migration of NCI-N87 and Hs766T cell lines by reducing mevalonolactone, FPP and GPP                                                                                   | [92] |
|                    | Simvastatin    | In vitro      | 0–60 μM                | -                 | Simvastatin inhibits the malignant behaviors of gastric cancer cells by simultaneously suppressing YAP and β-catenin signaling                                                                            | [93] |
| Colorectal cancer  | Simvastatin    | In vitro      | 0–20 μM                | -                 | Simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF-1-induced ERK and Akt expression via the downregulation of IGF-1R expression and proapoptotic ERK activation | [94] |
|                    | Simvastatin    | In vitro and vivo | 0–50 μM (In vitro) 20 mg/kg (In vivo) | -                 | Simvastatin activates the p38MAPK-p53-survivin cascade to cause HCT116 colorectal cancer cell apoptosis                                                                                                 | [95] |
|                    | Atorvastatin   | In vitro and vivo | 0–18 μM (In vitro) 15 mg/kg (In vivo) | Nobiletin         | Nobiletin/atorvastatin co-treatment synergistically induced extensive cell cycle arrest and apoptosis in colon cancer cells, and the enhanced chemopreventive activities against colon carcinogenesis in rats by the nobiletin/atorvastatin combination were highly synergistic | [96] |
| Cancer          | Statins                      | Type of study | Dose of administration          | Combination agent                | Findings                                                                                   | Ref. |
|----------------|------------------------------|---------------|---------------------------------|----------------------------------|--------------------------------------------------------------------------------------------|------|
| Liver cancer   | Fluvastatin and pravastatin | In vitro      | Fluvastatin: 0–50 μM            | PBR ligand                       | Statins inhibited the proliferation of HCC cells by inducing apoptosis and G1/S cell cycle arrest, and the efficacy of treatment with statins was synergistically enhanced by ligands of the peripheral benzodiazepine receptor (PBR) | [97] |
|                |                              |               | Pravastatin: 0–500 μM           |                                  |                                                                                            |      |
| Atorvastatin   |                              | In vitro and vivo | 0–40 μM (In vitro) 20 mg/kg (In vivo) | -                               | Atorvastatin induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway | [98] |
|                |                              | In vitro      | 0–30 μM                        | -                               | Atorvastatin mediated cell death occurred via inhibition of the PI3K/Akt pathway            | [99] |
| Simvastatin    |                              | In vitro and vivo | 0–40 μM (In vitro) 20 mg/kg (In vivo) | -                               | Simvastatin induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells | [100]|
| Pitavastatin   |                              | In vitro      | 0–20 μM                        | -                               | Pitavastatin inhibited growth and colony formation of liver cancer cell, and induced arrest of liver cancer cells at the G1 phase, furthermore, Pitavastatin promoted caspase-9/3 cleavage in liver cancer cells | [101]|
| Simvastatin    |                              | In vitro      | 0–20 μM                        | Receptor-interacting protein 140 | Simvastatin induced the apoptosis of SW7721 cells through the Wnt/β-catenin signaling pathway, as well as that receptor-interacting protein 140 and simvastatin exert a synergistic effect on the inhibition of cell proliferation and survival | [102]|
| Ovarian cancer | Lovastatin and atorvastatin  | In vitro      | 0–20 μM                        | -                               | Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression | [103]|
| Lovastatin     |                              | In vitro and vivo | 0–100 μM (In vitro) 12.5 mg/kg (In vivo) | -                               | Lovastatin affected the expression of genes associated with DNA replication, Rho/PLC signaling, glycolysis, and cholesterol biosynthesis pathways | [104]|
| Cancer          | Statins                        | Type of study | Dose of administration | Combination agent | Findings                                                                                                                                                                                                                                                                                                                                 |
|-----------------|--------------------------------|---------------|-------------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Lung cancer     | Pitavastatin and fluvastatin   | In vitro      | 0–100 μM                | Erlotinib         | Cytotoxicity mediated by statin/erlotinib co-treatment is synergistic and can overcome erlotinib resistance in K-ras mutated NSCLC and relies only on apoptosis                                                                                                                                                                                                 |
|                 | Simvastatin                    | In vitro and vivo | 0–100 μM (In vitro) 50 mg/kg (In vivo) | -                | Simvastatin potently disrupts growth and survival in human SCLC cells by inhibiting Ras signaling                                                                                                                                                                                                                                             |
|                 | Simvastatin                    | In vitro and vivo | 0–1 μM (In vitro) 10 mg/kg (In vivo) | -                | Simvastatin prevents proliferation and osteolytic bone metastases of lung adenocarcinoma cells via regulates CD44, P53, MMP family and inactivates of MAPK/ERK signaling pathway                                                                                                                                                                    |
|                 | Simvastatin                    | In vitro      | 0–10 μM                 | -                | Statins break the communication between cancer cells and mesenchymal stromal cells (MSCs) by inhibiting CCL3 secreted by cancer cells and IL-6 and CCL2 produced by MSCs                                                                                                                                                                               |
| Lymphoma        | Atorvastatin, fluvastatin and simvastatin | In vitro | 0–20 μM                 | -                | Statins induce lymphoma cells apoptosis by increasing intracellular ROS generation and p38 activation and suppressing activation of Akt and Erk pathways, through inhibition of metabolic products of the HMG-CoA reductase reaction including mevalonate, FPP and GGPP                                                                                                                                 |
| Lovastatin      | In vitro                       | 0–5 μM        | -                       |                  | Lovastatin inhibits malignant B cell proliferation by reducing membrane cholesterol, intracellular ROS, TRPC6 expression and activity, and intracellular Ca2+ +                                                                                                                                                                                                       |
| Brain cancer    | Simvastatin                    | In vitro      | 0–20 μM                 | -                | Simvastatin induces caspase-dependent apoptosis via the mevalonate pathway                                                                                                                                                                                                                                                                   |
|                 | Simvastatin                    | In vitro      | 0–20 μM                 | Temozolomide      | Simvastatin inhibited the autophagy flux induced by temozolomide by blocking autophagosome formation                                                                                                                                                                                                                                          |
| Cancer                  | Statins                  | Type of study | Dose of administration | Combination agent | Findings                                                                 | Ref. |
|------------------------|--------------------------|---------------|-------------------------|-------------------|---------------------------------------------------------------------------|------|
| Melanoma               | Simvastatin and atorvastatin | In vitro      | 0–80 μM                 | TRAIL             | Statins enhanced TRAIL-induced apoptosis, due to suppression of the NF-κB and STAT3 transcriptional targets (including COX-2) and downregulation of cFLIP-L (a caspase-8 inhibitor) protein levels | [113]|
|                        | Pitavastatin            | In vitro      | 0–5 μM                  | Dacarbazine       | Combined pitavastatin and dacarbazine treatment activates apoptosis and autophagy resulting in synergistic cytotoxicity in melanoma cells | [114]|
|                        | Lovastatin              | In vitro      | 0–4 μM                  | -                 | Lovastatin induces apoptosis in multiple melanoma cell lines via a geranylation-specific mechanism through caspase-dependent signaling | [115]|
|                        | Simvastatin              | In vivo       | 50 mg/kg                | -                 | Statin lowers PD-1 expression in CD8+ T cells and effectively restores antitumor activity | [116]|
| Esophageal carcinoma   | Simvastatin, lovastatin and pravastatin | In vitro      | 0–100 μM                | -                 | Statins inhibit proliferation and induce apoptosis in EAC cells via inhibition of Ras farnesylation and inhibition of the ERK and Akt signaling pathways | [117]|
| Bile duct cancer       | Simvastatin              | In vitro      | 0–500 μM                | -                 | Simvastatin suppressed cell proliferation by inducing G1 phase cell cycle arrest in bile duct cancer cells. Furthermore, it induced apoptosis via caspase-3 activation, downregulated the expression of the Bcl-2 protein, and enhanced the expression of the Bax protein. Moreover, simvastatin suppressed the expression of the IGF-1 receptor and IGF-1-induced ERK/Akt activation | [118]|
|                        | Simvastatin              | In vitro      | 0–100 μM                | -                 | Simvastatin induces cholangiocarcinoma cancer cell death by disrupting Rac1/lipid raft colocalization and depression of Rac1 activity | [119]|
| Osteosarcoma           | Simvastatin              | In vitro and vivo | 0–5 μM (In vitro) 40 mg/kg, 50 mg/kg or 80 mg/kg (In vivo) | -                 | Simvastatin induces apoptosis in osteosarcoma cells via activation of AMPK and p38 MAPK | [120]|
|                        | Simvastatin and fluvastatin | In vitro      | 0–5 μM                  | -                 | Simvastatin inhibits G1/G0 progression in the mevalonate pathway, and then inhibit signal transduction in the Ras/ERK and Ras/Akt pathways, thereby inhibiting bFGF, HGF, TGF-β expression in LMB cells | [121]|

Table 3 (continued)
| Cancer                                           | Statins            | Type of study | Dose of administration | Combination agent                        | Findings                                                                                                                                                                                                 | Ref.       |
|-------------------------------------------------|--------------------|---------------|------------------------|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Head and neck squamous cell carcinoma           | Lovastatin         | In vitro      | 0–50 μM                | -                                        | Lovastatin activates AMPK-p88MAPK-p63-survivin cascade to cause FaDu hypopharyngeal carcinoma cell death                                                                                                  | [122]     |
|                                                | Lovastatin         | In vitro      | 0–10 μM                | Chemotherapeutic drugs (cisplatin, cyclophosphamide, doxorubicin and paclitaxel) and Photodynamic therapy | Lovastatin inhibited the CSC properties and induced apoptosis and cell cycle arrest in 5-8F and 6-10B nasopharyngeal carcinoma cell line, and lovastatin conferred enhanced sensitivity to the chemotherapeutic and photodynamic agents in nasopharyngeal carcinoma CSCs | [123]     |
|                                                | Simvastatin        | In vitro      | 0–100 μM               | Celecoxib                                | The combination of celecoxib and simvastatin has showed a significant reduction in tumor cell viability, proliferation and secretion of IL-6 and IL-8                                                                 | [124]     |
|                                                | Simvastatin        | In vivo       | 5 mg/kg or 10 mg/kg    | Monocarboxylate transporter 1 inhibitor   | Simvastatin induces metabolic reprogramming in HNSCC mice, reducing lactate production and promoting cancer sensitivity to MCT1 inhibitor                                                                                 | [125]     |
|                                                | Pitavastatin       | In vitro      | 0–0.5 μM               | -                                        | Pitavastatin activates the FOXO3a/PUMA apoptotic axis by regulation of nuclear translocation of FOXO3a via Akt/FOXO3a or AMPK/FOXO3a signaling                                                                 | [126]     |
| Leukemia                                       | Atorvastatin       | In vitro      | 0–80 μM                | -                                        | Atorvastatin exerts antileukemic activity via inhibiting mevalonate-YAP axis in K562 and HL60 cells                                                                                                           | [127]     |
|                                                | Simvastatin        | In vitro      | 0–10 μM                | -                                        | Simvastatin exhibited anti-leukemic effect in human AML cells in vitro, especially at NRAS<sup>G12D</sup> mutant AML cell line                                                                                   | [128]     |
|                                                | Simvastatin        | In vitro      | 0–10 μM                | Bergamottin                              | Simvastatin and bergamottin potentially preventing and treating cancer through modulation of NF-kB signaling pathway and its regulated gene products                                                               | [129]     |
| Multiple myeloma                               | Pravastatin        | In vitro      | 0–0.9 μM               | -                                        | Pravastatin induces cell cycle arrest in G0/G1 and decreased production of growth factors in Multiple Myeloma cell line                                                                                       | [130]     |
|                                                | Simvastatin        | In vitro      | 0–10 μM                | -                                        | Simvastatin induced S-phase cell cycle arrest and apoptosis of multiple myeloma cells through the Chk1–Cdc25A-cyclin A/CDK2 pathway                                                                             | [131]     |
| Kidney cancer                                  | Simvastatin and fluvastatin | In vitro and vivo | 0–2 μM (in vitro) 10 mg/kg (in vivo) | Everolimus                               | Combination statins and mTOR inhibitor induced a robust activation of retinoblastoma protein via inhibits KRAS or Rac1 protein prenylation, and statins treatment also enhanced the efficacy of an mTOR inhibitor in RCC xenograft models                           | [132]     |
### Table 3 (continued)

| Cancer               | Statins | Type of study | Dose of administration | Combination agent | Findings                                                                                     | Ref. |
|----------------------|---------|---------------|------------------------|-------------------|-----------------------------------------------------------------------------------------------|------|
| Gallbladder cancer   | Lovastatin | In vitro and vivo | 0–50 μM (in vitro) 50 mg/kg (in vivo) | Cisplatin         | Lovastatin sensitized GBC cells to cisplatin-induced apoptosis and suppressed the activation of CHK1, CHK2, and H2AX during DNA damage response, and subcutaneous xenograft mice model suggested lovastatin promoted the therapeutic efficacy of cisplatin, and significantly prolonged the survival times of tumor-bearing mice | [133]|
| Endometrial cancer   | Simvastatin | In vitro  | 0–12 μM               | Metformin         | Combination simvastatin and metformin synergistically inhibits endometrial cancer cell viability mediated by apoptosis and mTOR pathway inhibition | [134]|

**Abbreviations:** AML Acute myeloid leukemia, CSCs Cancer stem cells, EAC Esophageal adenocarcinoma, GBC Gallbladder cancer, HNSCC Head and neck squamous cell carcinoma, MCT1 Monocarboxylate transporter 1, PBR Peripheral benzodiazepine receptor, RCC Renal cell carcinoma, TRAIL TNF-related apoptosis inducing ligand
metabolic dependence. The mevalonate pathway is an important and complex signaling pathway for the production of various isoprenoids, such as cholesterol, vitamin D, lipoproteins, polyol and ubiquinone [136]. Accumulating evidence indicates that mevalonate pathway (Fig. 3) flux, which is an absolute requirement for all cells, is increased in carcinogenic lesions and is a general feature of cancer [137]. This increased demand for mevalonate is a hallmark of tumorigenesis, and the increased availability of mevalonate pathway intermediates leads to adaptive changes that promote the adaptability of tumor cells [138]. A central motivation for targeting the mevalonate pathway is that selective and well-tolerated inhibitors already exist. Statins block HMGCR synthesis of mevalonate and are prescribed for the treatment of hypercholesterolemia in millions of people. Moreover, numerous in vivo and in vitro studies have shown that statins exert anti-cancer properties by inhibiting the mevalonate pathway. Here, we further divide these effects into those that are induced via non-cholesterol-mediated pathways and cholesterol-mediated pathways.

**Non-cholesterol-mediated pathways**

The mevalonate pathway starts with acetyl-CoA, which is derived from the decarboxylation of pyruvate, the final product of glycolysis. Three molecules of acetyl-CoA are then condensed into 3-hydroxyglutaryl-CoA, which is converted to mevalonate by HMGCR [139] in

![The mevalonate pathway and its transcriptional regulation.](image-url)

**Fig. 3** The mevalonate pathway and its transcriptional regulation. The mevalonate pathway begins with the end-product of glycolysis, acetyl-CoA, which is metabolized through several enzymatic steps to mevalonate, IPP, GPP, FPP, GGPP and cholesterol. Both FPP and GGPP can be post-translationally added to proteins, especially small monomeric GTPases (such as Ras, Rho, or Rac). Cholesterol is produced by cells via the mevalonate pathway or LDLR-mediated LDL endocytosis from the serum. When intracellular cholesterol levels are low, SCAP mediates the translocation of SREBP2 to the Golgi apparatus, where it is cleaved by proteases. The active N-terminal fragment is released and translocated to the nucleus, where it binds to the SRE regions of the HMGCR and LDLR promoters to induce gene expression. The inhibitory feedback mechanism mediated by cholesterol is indicated in blue. The mevalonate pathway can be blocked by statins.
a reaction that represents the rate-limiting step in this pathway. Mevalonate is then phosphorylated by mevalonate kinase and metabolized to isopentenyl pyrophosphate (IPP) [140–142], which is the factor that defines the key role of the mevalonate pathway in the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) via reactions that are catalyzed by farnesyl diphosphate synthase (FDPS) and GGPP synthase (GGPPS) [141, 143]. FPP is the basic component required for the production of squalene, which is a precursor of cholesterol and a key product of the mevalonate pathway. Cholesterol is mediated by additional enzymes, such as squalene epoxidase and squalene synthase [144, 145]. Cholesterol plays a vital role in the establishment and maintenance of the structure and function of cellular membranes. It is also a precursor of steroid hormones, vitamin D and bile acids [146, 147]. In addition, cholesterol is essential for the biogenesis of lipid rafts composed of lipids and proteins. These dynamic assemblies float within the cell membrane and participate in membrane transport, signal transduction, and cell polarization [148]. The synthesis of FPP and GGPP is essential for the post-translational modification referred to as prenylation of various proteins. This reaction is mediated by farnesyltransferase (FTase) I and geranyltransferases (GGTases) I and II. The localization, membrane anchoring and function of hundreds of signaling proteins depend on post-translational prenylation [139, 149]. These proteins include small monomeric GTPases (guanosine-triphosphate hydrolase) (e.g. Ras, Rho or Rac) and the γ-subunit of G-protein coupled receptors, which are involved in numerous important intracellular signaling pathways [150]. These small monomeric GTPases promote their anchoring and activation on the plasma membrane through isoprenylation and association of these signaling molecules with effectors to regulate a wide range of cellular functions, such as endocytosis/exocytosis, differentiation, cytoskeletal rearrangement and contraction, migration, apoptosis, and proliferation [151, 152]. Inhibition of HMGCR by statins depletes the pools of mevalonate (MA), IPP, FPP and GGPP in cells. This process interferes with the function of Ras and Rho family GTPases [153–157]. Indeed, lower GGPP and FPP concentrations, leading to reduced RAS and Rho isoprenylation, signal transduction, and DNA synthesis, are important functional consequences of statins in the treatment of cancer [119, 158–162]. Inhibiting the farnesylation of these proteins restricts their activity and might hinder cancer cell proliferation [163, 164]. Studies have shown that the inhibitory effect of simvastatin on the proliferation, migration and invasion of the gastric cancer cell lines MKN45 and MGC803 is due to a reduction in GGPP and RhoA activity mediated by inhibition of β-catenin and the Yes-associated protein (YAP) signaling pathways. Statins activate the intrinsic apoptotic pathway by disrupting the prenylation of key regulatory proteins. Therefore, the depletion of isoprenoids leads to the apoptosis of a variety of cancer cells [112, 165]. Simvastatin has also been shown to significantly inhibit the proliferation and migration of two cell lines of intestinal (NCI-N87) and diffuse (Hs746T) metastatic gastric tumor histological subtypes. Furthermore, the anti-proliferative effects of simvastatin in gastric cancer cells were reversed by the addition of mevalonate, FPP and GPP [92]. Simvastatin also activates caspase-3/-7/-9, which in turn induce apoptosis in human cancer cell lines through depletion of isoprenoids, a precursor to the prenylation of the small Rho GTP-enzyme [73, 166]. Fujiwara et al. reported that statins promote cell death by increasing the activation of caspases-3/-9, inducing Bcl-2 interacting mediator of cell death (Bim) expression, arresting the cell cycle at the G1 phase, and by decreasing the mitochondrial membrane potential (Δψm) through inhibition of Ras/ERK and Ras/mTOR pathways [167]. Statins stimulate membrane FasL expression and lymphocyte apoptosis via the RhoA/Rho-associated protein kinase (ROCK) pathway in murine melanoma cells in vitro [168]. A recent study showed that statins inhibit pyrimidine nucleotide biosynthesis by inhibiting the mevalonate pathway, and also induce oxidative stress and apoptosis in p53-deficient cancer cells [169]. Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects [170]. Lovastatin-induced MCF-7 cancer cell death is mediated via the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK)-p38 mitogen-activated protein kinase (p38MAPK)-p53-survivin signaling cascade [74]. Yin et al. found that pituitary tumor-transforming gene 1 (PTTG1) was significantly overexpressed in malignant breast cancer cell lines, and simvastatin downregulates its expression by inhibiting GGPP [171]. Freed-Pastor et al. revealed that mutant p53 can disrupt mammary acinar morphology by up-regulating the mevalonate pathway, thereby exerting a carcinogenic effect, while statins inhibit the mevalonate pathway to exert a tumor suppressor effect [172]. Epithelial-to-mesenchymal transition (EMT), which is an effective mechanism of cancer metastasis, is a dynamic multi-gene programming cycle [173]. Lipophilic statins have been found to function as antagonists of EMT signaling pathways in stem-like cells in breast cancer by inhibiting the mevalonate pathway [174]. In prostate cancer, lovastatin and simvastatin inactivate RhoA, thereby inducing cell apoptosis and cell cycle arrest in the G1 phase [90]. In ovarian cancer, statins promote cell apoptosis in a dose-dependent manner via a GGPP-mediated mechanism.
The complexity of these precisely controlled regulatory mechanisms ensures that cholesterol homeostasis is maintained within cells [195]. Dysregulation of cholesterol homeostasis or key molecules in cholesterol pathways, but also related to inflammasome- and miRNA-mediated cancer development. SREBP2 not only regulates the transcriptional activity of cholesterol biosynthesis genes and LDLR-mediated cholesterol influx, but also regulates the transcriptional activity of Nod-like receptor protein 3 (NLRP3) inflammasome-related inflammation. The causal relationship between chronic inflammation and cancer is widely established. Inflammasomes, which are large intracellular multi-protein signaling complexes formed in response to inflammation, participate in the activation of inflammatory protease caspase-1 and the pro-inflammatory cytokines interleukin (IL)-1β and IL-18 [196]. NLRP3 regulation is closely related to the development and progression of tumors, including head and neck squamous cell carcinoma [197], colorectal cancer [198] and breast cancer [199]. MicroRNA 33 (miRNA33) binds to the SREBP2 gene to positively regulate SREBP2 expression. Hyperactivation of cholesterol biosynthesis leads to uncontrolled cell growth [200].

Newly synthesized free cholesterol is transported to subcellular membranes by cholesterol transfer protein; however, to avoid excessive accumulation of free cholesterol, surplus cholesterol is esterified by acyl-CoA:cholesteryl acyltransferase 1 (ACAT1) to form cholesteryl esters (CEs), which are stored as lipid droplets (LDs) in cells [201]. Although CEs serve as a cholesterol reservoir, the accumulation of CEs or ACAT1 overexpression promote tumorigenesis. In a xenograft model of glioblastoma, ACAT1 ablation was shown to reduce tumor progression [202]. ACAT1 overexpression was also found in hepatocellular carcinoma [203]. In addition, the migration ability of breast cancer cells and the progression of prostate cancer was found to be suppressed by inhibiting the expression of ACAT1 [204, 205]. When de novo biosynthesis is the main source of intracellular cholesterol, most cells acquire cholesterol from LDL in the circulatory system via LDLR-mediated endocytosis [206]. Proprotein-convertase-subtilisin-kexin type-9 (PCSK9) overexpression promotes lysosomal degradation of LDLR [207], leading to hypercholesterolemia and ultimately, the occurrence of hepatocellular carcinoma [208].

Excess cholesterol also produces oxysterols, which are natural ligands for liver X receptors (LXRs). The binding of cholesterol to LXRs triggers conformational changes of the receptor, thereby enhancing the interaction with the co-activator protein and promoting the transcription of cholesterol efflux-related genes [209], including ATP-binding cassette (ABC) subfamily A member 1 (ABCA1), ABC subfamily G member 1 (ABCG1), and ABCG5/8. The excess cholesterol can be exported to lipid-poor apolipoprotein A-1 (ApoA-I) via ABCA1 or ABCG1, and generate high-density lipids proteins (HDLs), which are
transported back to the liver [210–213]. When the intracellular cholesterol level is high, the LXR can upregulate ABCA1 transcription [213]. However, in cancer cells, ABCA1 expression is inhibited via the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin complex 1 (mTORC1) pathway [200]. MiR-183 promotes the proliferation and anti-apoptotic properties of colon cancer cells by directly degrading ABCA1 mRNA to maintain high levels of intracellular cholesterol [214]. Similarly, miR-27a-3p also inhibits cancer cell apoptosis by blocking cholesterol efflux or targeting ABCA1 [215]. LXR overexpression has been shown to have anti-proliferative effects in gastric cancer cells [216]. Cholesterol and its oxygenated derivatives bind with high affinity to the G protein-coupled receptor (GPCR) known as smoothened receptor (SMO), which activates the Sonic Hedgehog (SHH) pathway [217]. The SHH pathway is considered to be an oncogenic signaling cascade based on its ability to promote cell cycle progression and stem cell proliferation by increasing glioma-associated oncogene homolog 1 (GLI1) activity, which subsequently activates hedgehog targeting genes, thereby enhancing tumor formation [218]. Statins arrest SHH signaling in medulloblastoma cells and fibroblasts by inhibiting cholesterol synthesis, thus attenuating tumor proliferation [219]. Similarly, Fan et al. recently found that statins suppress medulloblastoma growth without bone toxicity by repressing hedgehog signaling in tumor cells [220]. These studies illustrate the inseparable correlation between cholesterol and cancer, and reveal that statins exert anticancer properties by inhibiting the de novo synthesis of cholesterol.

**Statins regulate autophagy**

Both autophagy and apoptosis are important biological phenomena involved in various processes such as development and growth. The major distinction between autophagy and apoptosis is their purpose. For example, during stress conditions, autophagy primarily targets certain toxic components to preserve cell survival [221, 222]. When autophagy is insufficient to reduce stress and compensate for cellular damage, this results in autophagic cell death, which is similar to apoptosis [223, 224]. Since the discovery of autophagy, numerous studies have shown that autophagy is associated with the progression of pathological conditions, especially cancer [225–227]. Autophagy has been shown to reduce the viability of tumor cells or play a protective role in cancer. Thus, autophagy seems to play a dual role in tumorigenesis and tumor progression [228]. The tumor-suppressive function of autophagy is primarily important in the early stages of cancer development, representing a critical quality control mechanism that maintains genomic integrity by regulating the degradation of damaged proteins or organelles (such as dysfunctional mitochondria) [228, 229]. Autophagy also facilitates oncogene-induced senescence [230] and contributes to cancer immune surveillance [231]. The tumor-promoting effects of autophagy are exerted mainly in the later stages of tumor development. Due to the rapid proliferation of cancer cells, the nutritional requirements for anabolic pathways are high. Autophagy contributes to cancer cell metabolism by recycling cellular substrates [232]. Autophagy also promotes the survival of cancer cells under stress conditions, such as tumor hypoxia, nutrient deprivation or endoplasmic reticulum (ER) stress [233, 234]. In summary, interfering with autophagy is a reasonable therapeutic strategy to improving the effect of anti-cancer treatments in the clinic. A variety of anti-cancer drugs have been developed based on their ability to regulate autophagy. The first report of statin-induced autophagy showed that hydrophobic statins, such as simvastatin, induced autophagy in rhabdomyosarcoma A204 cells [235] through depletion of the GGPP pool [236]. After deletion of the autophagy-related gene 5 (ATG5) or ATG7 gene in SPC-A-1 cells, fluvastatin inhibits bone metastasis by inducing autophagy in lung adenocarcinoma cells [237]. In HEK293 human embryonic kidney cells, atorvastatin induces autophagy in a mevalonate (MEV) pathway-dependent manner by inhibiting GGPP synthesis [89]. Autophagy was induced in U251 cells by treatment with simvastatin for 24 h, and this effect was reversed by the addition of MEV, which again suggests that the MEV cascade is involved in statin-mediated autophagy [238]. In human leukemia cells treated with simvastatin for 24–72 h, the induction of autophagy flux appeared to be mediated by the inhibition of cholesterol production, rather than the synthesis of FPP or GGPP [239]. Atorvastatin induced autophagy in the Huh7 and HCT116 gastrointestinal tumor cell lines independent of the MEV pathway [240]. Simvastatin can impair autophagy flux and induce breast cancer cell death by stimulating the extracellular regulated protein kinases 1 and 2 (ERK1/2) and Akt pathways [79]. Lovastatin stimulates autophagy through the Rac/phospholipase C/inositol 1,4,5-triphosphate axis, and markedly decreases the viability and migration ability of malignant pleural mesothelioma tumor cells [241]. Due to the resistance of tumor cells to apoptosis-based therapy, and the stimulatory effect of cancer cell apoptosis on the survival and proliferation of neighboring cells, the induction of autophagic cell death is preferred to apoptosis as a strategy to combat cancer. Studies have shown that the combination lovastatin and farnesyltransferase inhibitors can stimulate non-apoptotic
Angiogenesis plays a critical role in cancer progression. Atorvastatin stimulates autophagy in human umbilical vein endothelial cells. Furthermore, high-dose atorvastatin activates apoptosis and inhibits angiogenesis. Atorvastatin stimulates autophagy through upregulation of light chain 3-phosphatidylethanolamine conjugate (LC3II), which effectively reduces proliferation and viability of cancer cells [243]. The benefits of statins as adjuvant therapy for cancer have been widely reported. The combination of lovastatin and cisplatin has been found to enhance expression of the autophagy marker LC3B-II and decrease the viability of cancer cells through the induction of autophagic cell death [244]. Autophagy has been shown to play a central role in the induction of chemotherapeutic resistance [245, 246]. The anti-cancer effects of the chemotherapeutic agent temozolomide (TMZ), which is used to treat glioblastoma (GBM), are markedly reduced by TMZ-induced autophagy. A recent study showed that simvastatin inhibits the autophagic flux induced by TMZ by blocking autophagosomes formation, thereby sensitizing glioblastoma cells to TMZ-induced cell death [112]. However, a recent study showed that atorvastatin reduces cell viability and promotes cervical cancer cell apoptosis by inducing the activation of caspase-3 and poly (ADP-ribose) polymerase (PARP) and upregulating Bim. However, atorvastatin induced cellular autophagy in cervical cancer cells, and pharmacologic inhibition of autophagy using autophagy inhibitors remarkably enhanced atorvastatin-induced apoptosis of cervical cancer cells [247].

In summary, statins are capable of modulating autophagy, making them promising candidates for the treatment of cancer. However, the regulatory effects of statins on autophagy require further clarification.

**Statins induce ferroptosis**

The term ferroptosis, which was coined in 2012 [248], is a form of programmed cell death (PCD) that differs from apoptosis, necrosis, pyroptosis and autophagy [249, 250]. Ferroptosis is associated with the occurrence of multiple diseases [251, 252] and its role in the treatment of cancer has attracted increasing attention [253–258]. In essence, ferroptosis is a process that occurs as a result of metabolic dysregulation, and is characterized by iron overload, lipid reactive oxygen species (ROS) accumulation, and lipid peroxidation [248]. Ferroptosis is inhibited by sequestration of free iron, inhibition of polyunsaturated fatty acid (PUFA) synthesis, or scavenging of ROS. Ferroptosis and lipid peroxidation are mainly controlled by three parallel systems: the glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis, the ferroptosis suppressor protein 1 (FSP1)/ubiquinone (CoQ10)/NAD(P)H axis and the GTP cyclohydrolase 1 (GCH1)/tetrahydrobiopterin (BH4)/phospholipid axis [259–261]. The induction of ferroptosis in tumor cells is a promising anti-tumor strategy.
Statins are associated with ferroptosis via the mevalonate pathway (Fig. 4), which is closely related to the regulation of the GSH/GPX4 and FSP1/CoQ10/NAD(P)H axes. The mevalonate pathway is crucial for the synthesis of GPX4 itself and generation of the CoQ10 backbone. IPP produced by the mevalonate pathway is the precursor of CoQ10. IPP positively regulates Sec-tRNA, which functions as a key regulatory element during the maturation of GPX4 [262, 263]. Blocking the rate-limiting enzyme in the mevalonate pathway by using statins compromises the efficient translation of GPX4 and consequently sensitizes cells to ferroptosis [264, 265]. It was recently revealed that the mechanism underlying the protective effect of CoQ10 is based on the ability of FSP1 to use CoQ10 as a substrate to hinder lipid autoxidation [259, 260]. A recent study showed that drug-resistant cancer cells in a high-mesenchymal cell state were sensitive to ferroptosis induced by GPX4 inhibition or statin treatment. Fluvastatin treatment decreased GPX4 expression in a time- and concentration-dependent manner and its effects are enhanced by combination with the direct GPX4 inhibitor RSL3 [264]. Therefore, in the absence of bioavailable GPX4 inhibitors, statins stand out as candidates for the therapeutic induction of ferroptosis in highly mesenchymal and chemotherapy-resistant cancer cells.

Statins induce pyroptosis
Pyroptosis is an inflammatory form of PCD that is distinct from autophagy and ferroptosis. It was first described in myeloid cells infected by pathogens or bacteria in 1992 [266–268]. Pyroptosis is characterized by cell swelling, rupture, lysis and release of pro-inflammatory molecules, such as IL-1β and IL-18 [269, 270] and is induced by members of the gasdermin superfamily, including GSDMA, GSDMB, GSDMC, GSDMD, and GSDME [271–276]. The inflammasome activates caspase family proteins to cleave gasdermin. The resulting active form of the protein translocates to the cell membrane, forming pores that lead to cell swelling, cytoplasmic outflow, cell membrane rupture and eventually cell pyroptosis [273–275]. Generally, GSDMD, which is downstream of inflammasome activation, is cleaved by inflammatory caspases (caspase1/4/5/11) to induce pyroptosis, while GSDME is cleaved by apoptotic caspases (caspase 3) to induce pyroptosis [272]. There are two main pathways of pyroptosis: the caspase-1-mediated canonical pathway and the caspase-4/5/11-mediated non-canonical pathway. In the canonical pathway, danger is sensed through inflammasomes, leading to the recruitment and activation of caspase-1, which activates inflammatory factors such as IL-18 and IL-1β and cleaves the N-terminal sequence of GSDMD. The activated form of GSDMD then bind to the cell membrane to generate pores and induce pyroptosis [277]. In the non-canonical pathway, human homologs caspase-4, 5 and murine caspase-11 recognize and bind to the bacterial lipopolysaccharide (LPS) and then cleave GSDMD, leading indirectly to caspase-1 activation and pyroptosis [271, 274].

Many studies have shown that pyroptosis is closely related to the occurrence and development of various diseases, such as cancer [267, 278, 279]. For example, recent studies have shown that the low GSDMD expression significantly promotes the proliferation of gastric cancer cells both in vivo and in vitro [280]. Zhou et al. demonstrated that that iron supplementation at appropriate doses in iron-deficient patients is sufficient to maximize the anti-tumor effects of clinical ROS-inducing drugs, and inhibit the growth and metastasis of melanoma cells through GSDME-dependent pyroptosis [281]. A recent study showed that atorvastatin inhibits pyroptosis through the long non-coding RNA (lncRNA) NEXN-AS1/NEXN pathway in human vascular endothelial cells [282]. In a mouse model of cardiac injury induced by coronary microembolization, rosuvastatin decreased the expression of NLRP3, caspase-1, interleukin-1β and GSDMD N-terminal domains, suggesting that this drug can protect against this type of cardiac injury by inhibiting pyroptosis [283]. However, the potential role of pyroptosis in the anti-tumor effects of statins remains to be fully elucidated.

Statins target the TME
Tumor microenvironment (TME) denotes the non-cancerous cells and components presented in the tumor, including molecules produced and released by them (Fig. 5). Over time, cancer has been recognized as an evolutionary and ecological process that involves constant, dynamic, and reciprocal interactions between cancer cells and TME [284]. The constant interaction between tumor cells and the TME plays a decisive role in tumor initiation, progression, metastasis, and response to therapy. The acquisition and maintenance of the hallmarks of cancer, such as maintained proliferation signaling, resistance to cell death, angiogenesis, activation of invasion and metastasis, and the induction of tumor-promoting inflammation, as well as the evasion of immune destruction, depend to varying degrees on the contribution of TME.

Given our increased understanding of the crucial roles of the TME in tumor development and therapeutic resistance, the focus of cancer research and treatment has gradually switched from a cancer-centric model to a TME-centric model. Efforts have been made to target components of the TME to achieve therapeutic benefits for cancer patients. We have introduced some specialized
microenvironments in TME, focusing on hypoxic niche, immune microenvironment, metabolism microenvironment, acidic niche, innervated niche, and mechanical microenvironment (Fig. 5) [285]. Compared with the whole TME, a specialized microenvironment seems to be a better target for cancer treatment. The anti-tumor effects of some conventional drugs have been shown to be mediated by targeting the TME. Statins have been observed to exert anti-tumor effects by targeting these specialized microenvironments.

In the metabolic microenvironment, simvastatin has been shown to induce metabolic reprogramming in a mouse model of head and neck squamous cell carcinoma (HNSCC) by reducing the production of lactic acid and cancer sensitivity to monocarboxylate transporter 1 (MCT1) inhibitor, thereby inhibiting HNSCC [125].

In the mechanical microenvironment, simvastatin repolarizes tumor-associated macrophages (TAM) and promotes M2-to-M1 phenotype switching of macrophages via cholesterol-associated LXR/ABCA1 regulation, thereby remodeling the tumor microenvironment and inhibiting EMT [286].

Statins are also reported to target the immune microenvironment through cytokines or chemokines and immune checkpoints. Statins inhibit the survival of lung cancer cells by inhibiting the secretion of CCL3 by lung cancer cells as well as IL-6 and CCL2 secretion by mesenchymal stromal cells, indicating the potential of statins as repurposed drugs for targeting the immune TME [108].

In inflammatory breast cancer (IBC), simvastatin blocks the activation of mesenchymal stem cells by decreasing IL-6 production [287]. A recent study showed that simvastatin can enhance the anti-tumor activity of CD8⁺ T cells by reducing cholesterol in the TME [116].

Hypoxia is induced in tumors by the outgrowth of cancer cells and unmatched angiogenesis and oxygen supply, accompanied by changes in the rate of cancer cell metabolism. Hypoxia activates vascular endothelial cells, upregulates vascular endothelial growth factor (VEGF) transcription, and stimulates excessive
angiogenesis, thereby influencing the TME and therapeutic effects [288–291]. Statins have been shown to inhibit GGPP biosynthesis, and signal transduction via the Ras/ERK and Ras/Akt pathways, thereby suppressing the expression of basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and transforming growth factor-β (TGF-β) in LM8 cells. These results suggest that statins are potentially useful as anti-angiogenic agents for the treatment of osteosarcoma [121].

In the acidic niche, statins inhibited the proliferation of the human synovial sarcoma cell line SW982 by reducing the production of GGPP [292]. Many studies have shown that statins can influence and regulate the central and the peripheral nervous systems [293–295]. However, there is no conclusive evidence to show that statins exert anti-cancer effects by targeting the innervated niche, and further studies are required to clarify this issue.

Thus, a large amount of evidence shows that statins can exert anti-tumor properties by targeting TME, and repurposing statins to target the TME has shown considerable advantages. These findings indicate that statins can target multiple microenvironments and highlight the great potential for their use in combination with approaches such as immunotherapy, chemotherapy, and targeted therapy.

**Maximizing efficacy and addressing shortcomings of conventional cancer therapy**

In recent years, many clinical and preclinical studies have shown the potential of statins to improve the efficacy of various cancer treatments when delivered before or in combination with other therapeutic interventions. Consequently, statins are increasingly considered as potential adjuvant agents in the treatment of cancer. In this regard, statins have unique advantages in that they are safe, well-tolerated and inexpensive, indicating that repurposing these agents may yield a cost-effective, low-toxicity adjuvant therapy for cancer patients. However, in the era of precision medicine, further investigation into drug combination strategies will remain an important area of research [296]. Here, we discuss not only the effects of various statins combination strategies for cancer therapy, but also their unique benefits in terms of addressing the shortcomings of conventional cancer therapy.

In preclinical studies, statins have shown great promise in combined therapies and may act synergistically with some types of widely used forms of chemotherapy. For example, using in vitro and in vivo metabolism tracking, McGregor et al. recently showed that pancreatic ductal adenocarcinoma (PDAC) tumors rely on CoQ synthesized by the mevalonate pathway, and that statins induce cellular oxidative stress via this pathway. Furthermore, simvastatin combined with mitogen-activated protein kinase (MEK) inhibitors was found to significantly enhance pancreatic tumor apoptosis in mice [297]. Taccioli et al. identified that dasatinib and statins are an effective combined strategy for inhibiting YAP/TAZ in cancer cells by interrogating the Mutations and Drugs Portal (MDP) [298]. Iannelli et al. demonstrated the ability of the valproic acid/simvastatin combination to sensitize metastatic castration-resistant prostate cancer cells to docetaxel and to revert docetaxel-resistance through mevalonate pathway/YAP axis modulation using both in vitro and in vivo models [299]. Adriamycin-based chemotherapy is the first-line treatment for osteosarcoma, but most patients will experience tumor recurrence and metastasis. Adriamycin treatment has been shown to induce a stem-like phenotype and promote metastatic potential in osteosarcoma cells by upregulating the Yamanaka factor KLF4. In addition, statins significantly reversed adriamycin-induced cancer stem cell properties and metastasis by downregulating KLF4. Simvastatin also significantly inhibited adriamycin-enhanced tumorigenesis of KHOS/NP cells in vivo. These data indicate that the combined use of statins should be considered for selective inhibition of KLF4 in the development of osteosarcoma therapeutics [300]. Similarly, as the main therapeutic strategy for colorectal cancer, 5-FU-based treatment options have some shortcomings, including the risk of chemotherapy resistance. Recent evidence suggests that simvastatin may enhance the sensitivity of C26 mouse colon cancer cells to 5-FU treatment [301]. Pereira et al. found that statins temporarily modulated the epidermal growth factor receptor (EGFR) and prostate specific membrane antigen (PSMA) on the surface of tumor cells, which enhanced the tumor-binding avidity of the monoclonal antibodies panitumumab, cetuximab and hu591, thereby synergizing with the antitumor effects of these agents [302]. It has also been reported that lovastatin enhanced the sensitivity of gallbladder cancer to cisplatin [303].

Similarly, in clinical studies, statins have been shown to be effective in adjuvant cancer treatment. Recent clinical studies have shown that high-intensity statins are associated with improved clinical activity of PD-1 inhibitors, and the combined application can improve the prognosis of patients with malignant pleural mesothelioma and advanced non-small cell lung cancer [69]. A recent cohort study from Taiwan has shown that statins are associated with increased survival in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and exert synergistic anti-cancer effects [304]. Similarly, another cohort study of 1,835 patients with gastric cancer from Taiwan, suggested that the statin use improves the overall survival
of patients with gastric cancer after surgery and adjuvant chemotherapy [60]. A recent multicenter observational retrospective study showed that the use of statins was independently associated with an increased objective response rate (ORR) of cancer patients treated with PD-1/PD-L1 inhibitors [305]. Interestingly, both metformin and statins significantly reduced prostate cancer tumor invasiveness, and this effect was enhanced (in vitro and vivo) when used in combination [306]. Recently, Longo et al. also found that phosphodiesterase (PDE) inhibitors can enhance statin-induced apoptosis, which may pave the way for the combination of PDE inhibitors and statins in the treatment of hematological malignancies [307]. Therefore, a large body of preclinical and clinical evidence shows that statins play a synergistic anti-tumor role when administered in combination with conventional cancer therapy. This evidence may provide references for the inclusion of statins in the future cancer therapy.

Interestingly, statins can not only maximize the efficacy of conventional cancer therapy, but also address the shortcomings of conventional cancer therapy. Although great progress has been made in the field of cancer therapy, chemotherapy and radiotherapy remain the mainstay of cancer therapeutic modalities and are extensively used in combination with surgery. While radiotherapy and chemotherapy can improve the survival of cancer patients, these treatments are also associated with serious shortcomings that influence the quality of life of cancer patients. Despite great efforts in the development of new cancer treatment strategies, limited attention has been paid to addressing the shortcomings of cancer treatment. Therefore, in addition to improving survival rates, clinical interventions are urgently needed to minimize the shortcomings and side-effects induced by radiotherapy and chemotherapy and improve the quality of life of cancer patients. In recent years, statins have attracted widespread attention due not only to their anti-tumor properties, but also their potential to address the shortcomings and side-effects of radiotherapy and chemotherapy.

Cisplatin is one of the most widely used anticancer drugs in the treatment of a variety of malignant tumors. It is also the most ototoxic drug in clinical use, causing permanent hearing loss in approximately 50% of treated patients [308–312]. A recent study showed that atorvastatin significantly reduced the incidence and severity of cisplatin-induced hearing loss [313]. In a propensity score-matched cohort study, statin-exposed women had a lower risk of heart failure (HF)-related hospital presentations after anthracycline chemotherapy for early breast cancer, with non-significant trends toward lower risk following treatment with trastuzumab. These findings support the ability of statins to prevent the cardiotoxicity of chemotherapy [314]. In addition, a fraction of patients undergoing androgen deprivation therapy for advanced prostate cancer will develop recurrent castrate-resistant prostate cancer in bone. But recently, Pan et al. found that statins can reduce castration-induced bone marrow adiposity and prostate cancer progression in bone [315]. The safety and toxicity profiles of statins also represent advantages for their use as adjuvant therapy in addressing the shortcomings and side-effects of cancer treatments. Statins used alone and in combined regimens have shown unparalleled advantages as anti-cancer agents and addressing the shortcomings and side-effects of conventional cancer treatments. However, the molecular mechanisms by which statins address these shortcomings and side-effects require clarification to provide a basis for the rational combination of statins and anticancer drugs to optimize cancer therapy.

**Conclusions and future perspectives**

Statins belong to a class of lipid-lowering drugs that were originally developed to treat cardiovascular disease. In recent decades, statins have been found to have non-lipid-related effects and are widely recognized as pleiotropic drugs. The anti-tumor properties of statins have received the most attention and have been confirmed in numerous preclinical studies. Here, we have summarized the latest information relating to the anti-tumor mechanisms of statins. The mevalonate pathway was the first anti-tumor mechanism of statins to be discovered and is also the most comprehensively characterized. Statins modulate cell proliferation, differentiation, and apoptosis by depletion of mevalonate pathway intermediates, which interferes with the post-translational modification and activation of small GTPases and their downstream signaling. In addition, the mevalonate pathway is required for the de novo biosynthesis of cholesterol and several studies have shown that cellular cholesterol levels are significantly associated with cancer. Therefore, we have described the role of the mevalonate pathway in anti-tumor mechanism of statins from the perspectives of the cholesterol-mediated pathway and the non-cholesterol-mediated pathways. Moreover, we have summarized the latest discoveries that further clarify the anti-tumor mechanisms of statins, including autophagy, ferroptosis, targeting the tumor microenvironment, and pyroptosis. The improved understanding of these mechanisms will help elucidate the anti-tumor properties of statins and guide clinical trials of statins, thus facilitating the identification of novel cancer therapies.

In recent years, a large number of clinical and epidemiological studies on statins have been conducted, yielding both positive and negative results. Therefore,
more well-designed clinical trials are required to validate the anti-cancer effects of statins. However, the value of statins as therapeutic agents against cancer in humans remains an area of active research. Although the clinical evidence that supports the use of statins as a monotherapy for cancer is not convincing, several preclinical and clinical studies indicate that statins potentiate the effects of currently used cancer therapies when administered in combination. Furthermore, statins have been shown to address the shortcomings and side-effects caused by anticancer agents. Nevertheless, difficulties in statin administration at high doses remain unsolved, so statins are currently unlikely to be prescribed as a monotherapy. Therefore, we advocate the use of statins as an adjuvant therapy for cancer, which may be a more promising strategy than statin monotherapy. In addition, the large number of preclinical studies that have provided evidence of the anti-cancer properties of statins, as well as their safety and lack of toxicity, indicate that statins are ready to be investigated in well-designed prospective clinical trials, with lipophilic statins likely leading the charge.

In conclusion, statins are a potential adjuvant to cancer therapy, and more well-designed clinical trials are required to translate this potential to benefit patients.

Abbreviations

ABC: ATP-binding cassette; ABCA1: ATP-binding cassette subfamily A member 1; ABCG1: ATP-binding cassette subfamily G member 1; ACAT1: Acyl-CoA:cholesteryl acyltransferase 1; Akt: Protein kinase B; AML: Acute myeloid leukemia; AMPK: AMP-activated protein kinase; ApoA1: Apolipoprotein A-1; ATG: Autophagy-related gene; bFGF: Basic fibroblast growth factor; BH4: Tetrahydrobiopterin; Bim: Bcl-2 triphosphate hydrolase; HCC: Hepatocellular carcinoma; HDLs: High-density lipoproteins; Glioma-associated oncogene homolog 1; GPCR: G protein-coupled receptor; GCH1: GTP cyclohydrolase 1; GGPP: Geranylgeranyl pyrophosphate; GGPPS: Geranylgeranyl pyrophosphate synthase; FSP1: Ferroptosis suppressor protein 1; FTase: Farnesyl-diphosphate synthase; FPP: Farnesyl diphosphate synthase; ERK: Extracellular regulated protein kinase; FAC: Fluorouracil, adriamycin; EMT: Epithelial-to-mesenchymal transition; ER: Endoplasmic reticulum; ERO: Extracellular regulated protein kinase receptor-tyrosine kinase inhibitors; EMT: Epithelial-to-mesenchymal transition; FPG: Fasting plasma glucose; GPCRs: G protein-coupled receptors; LDLs: Lipoprotein lipase; LDLR: Low-density lipoprotein receptor; MAPK: Mitogen-activated protein kinase; MDR: Multi-drug resistance; MDR1: Multidrug resistance gene 1; MEK: Mitogen-activated protein kinase; MEV: Mevalonate; MR: Multiple myeloma; mTORC1: Mechanistic target of rapamycin complex 1; NLRP3: Nod-like receptor family pyrin domain containing 3; NR: Not reported; NSCLC: Non-small cell lung cancer; ORR: Objective response rate; OS: Overall survival; PARP: Poly(ADP-ribose) polymerase; PBR: Peripheral benzodiazepine receptor; PCa: Prostate cancer; PCI: Programmed cell death; PCSK9: Proprotein-convertase-subtilisin-kexin type-9; PDAC: Pancreatic ductal adenocarcinoma; PDE: Phosphodiesterase; PD-1: Programmed death receptor-1; PFS: Progression-free survival; P3K. Phosphatidylinositol-3-kinase; PSA: Prostate specific membrane antigen; PTEN: Phosphatase and tensin homolog; PTTG1: Pituitary tumor-transforming gene 1; PUFA: Polysaturated fatty acid; P38MAPK: P38 mitogen-activated protein kinase; RCC: Renal cell carcinoma; ROCK: Rho-associated protein kinase; ROS: Reactive oxygen species; RR: Relative risk; SREBPs: Sterol regulatory elements; TAE: Transcatheater arterial embolization; TAM: Tumor-associated macrophages; TGF-β: Transforming growth factor-β; TIM: Tumor microenvironment; TMZ: Temozolomide; TRAIL: TNF-related apoptosis inducing ligand; VEGF: Vascular endothelial growth factor; YAP: Yes-associated protein; 5-FU: 5-Fluorouracil; DPP4: Dipeptidyl peptidase 4; LXRα: Liver X receptor alpha; MCT1: Monocarboxylate transporter 1; MDR: Multi-drug resistance gene 1; MEK: Mitogen-activated protein kinase; MEV: Mevalonate; MM: Multiple myeloma; mTORC1: Mechanistic target of rapamycin complex 1; NLRP3: Nod-like receptor family pyrin domain containing 3; NR: Not reported; NSCLC: Non-small cell lung cancer; ORR: Objective response rate; OS: Overall survival; PARP: Poly(ADP-ribose)
3. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2013;34(9):508–17. PMID: 23928289.

4. Mohammadzadeh N, Montecucco F, Carbone F, Xu S, Al-Rasadi K, Saehekbak A. Statins: Epipads with effects on endothelial health? Eur J Clin Invest. 2020;S0091-6749(19)30388-5. PMID: 32854143.

5. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel TM, Morreau H, Hommes DW, Peppelenbosch MP, van den Brink GR, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell viability via the bone morphogenetic pathway. Gut. 2011;60(11):1544–53. PMID: 21551187.

6. Piccollo S, Cordenonsi M, Dupont S. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res. 2013;19(18):4925–30. PMID: 23797907.

7. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrihn A, Ingallina E, Sommaggio R, Piazza S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(9):357–66. PMID: 24658867.

8. Howe K, Sanat F, Thuman AE, Coleman T, Plant N. The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PPAR, CAR and FXR, as well as their downstream target genes. Xenobiotica. 2011;41(7):519–29. PMID: 21476904.

9. Dulak J, Jokubaviciute A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Drug Targets. 2005;5(8):579–94. PMID: 16375664.

10. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

11. Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Brahes J, Carvalja J, Gejman R, Owen G, Cuello M. Lipophilic but not hydrophilic statins selectively induce cell death in gaunecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2010;14(5):1180–93. PMID: 19432822.

12. Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, Hsi S, et al. Repurposing statins by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2019;40(6):573–9. PMID: 31059259.

13. Kazi DS, Penko JM, Bibbins-Domingo K. Statins for primary prevention of cardiovascular disease: review of evidence and recommendations for clinical practice. Med Clin North Am. 2017;101(4):689–104. PMID: 28393863.

14. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

15. Chung JW, Cha J, Lee MJ, Yu IW, Park MS, Seo WK, Kim ST, Bang OY. Statin use is associated with improved survival of patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: a nationwide matched cohort study. Cancers. 2020;12(8):2055. PMID: 32722425.

16. Cho M, Yoo T, Jeong S, Shin DW. Association of aspirin, metformin, and statin use with gastric cancer incidence and mortality: a nationwide cohort study. Cancer Prev Res (Phila). 2017;11(1):95–104. PMID: 28027679.

17. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

18. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

19. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

20. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

21. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

22. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

23. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.

24. Hamelin BA, Tourjegeon J. Hydrophilicity/lipophilicity: relevance for the pharmacological and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37. PMID: 9505869.
42. Cote D, Rosner B, Smith-Warner S, Egan K, Stampfer M. Statin use, hyperlipidemia, and risk of glioma. Eur J Epidemiol. 2019;34(11):997–1011. PMID: 31559554.

43. Sperling C, Verdoort F, Friis S, Dehlendorff C, Kjaer S. Statin use and risk of endometrial cancer: a nationwide registry-based case-control study. Acta Obstet Gynecol Scand. 2017;96(2):144–9. PMID: 27891577.

44. Nayan M, Punjani N, Juurlink D, Austin P, Kulkarni G, Uleryk E, Hamilton R. Statin use and kidney cancer survival outcomes: a systematic review and meta-analysis. Cancer Treat Rev. 2017;52:105–16. PMID: 27992843.

45. Sanfilippo K, Keller J, Gage B, Luo S, Wang T, Moskowitz G, Gumbel J, Lebo N, Griffiths R, Hall S, Dimitroulakos J, Johnson-Obaseki S. Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. Head Neck. 2018;40(8):1697–706. PMID: 29934959.

46. Garwood ER, Kumar AS, Baethner FL, Moore DH, Au A, Hyton N, Flowerson CL, Garber J, Lesnikoski BA, Hwang ES, et al. Fluvasitatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119(1):137–44. PMID: 19728082.

47. Feldt M, Borshadottir O, Kimbong S, Jirström K, Bendahl PO, Veerla S, Longo J, Hamilton RJ, Masoomian M, Khurram N, Branchard E, Mullen FA, Sleijfer S. The addition of pravastatin to chemotherapy in advanced local breast cancer. Cancer Res Treat. 2021. https://doi.org/10.4134/crt.2020.1024. PMID: 33706523.

48. Longo J, Hamilton RJ, Masoomian M, Khurram N, Branchard E, Mullen PJ, Elbaz M, Hersey K, Chadwick D, Gha S, et al. A pilot window-of-opportunity study of preoperative fluvasitatin in localized prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):630–7. PMID: 23203069.

49. Jin ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KY, et al. Simvastatin plus capcitabine-cisplatin versus placebo plus capcitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014;50(16):2822–30. PMID: 25218337.

50. Konings IR, van der Gaart A, van der Wijk LJ, de Jongh FE, Eksens FA, Sleijfer S. A randomized phase II study of gemcitabine plus fluorouracil and oxaliplatin in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2010;28(18):2300–4. PMID: 20727735.

51. Han JY, Kang JH, Lee SH, Yoo NJ, Hyung LS, Moon YJ, Kim HT, Lee JS. A randomized phase II study of gemcitabine plus fluorouracil and oxaliplatin in patients with previously untreated advanced pancreatic cancer: a randomised controlled trial. Br J Cancer. 2001;84(7):886–91. PMID: 11264666.

52. Nielsen S, Nordrengaard B, Bojesen S. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367(19):1792–802. PMID: 22947939.

53. Jouve JL, Lecomte T, Bouché O, Barbier E, Khemissa Alouz F, Riachi G, Nguyen Khac E, Ollivier-Hournard I, Debette-Gratien M, Faroux R, et al. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(3):516–22. PMID: 31125576.

54. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura F, Iarrobino NA, Gill B, Bernard ME, Mishra MV, Champ CE. Targeting tumor metabolism with statins during treatment for advanced-stage pancreatic cancer. Am J Clin Oncol. 2018;41(1):1125–31. PMID: 29509593.

55. Li, Bu Y, Z, Guan X, Zeng YX, Ma F. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Res Treat. 2017;164(1):1–11. PMID: 28432513.

56. Bonovas S, Filisoussi K, Taisiari N, Sitasar NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23(34):8606–12. PMID: 16266094.

57. Geybers MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. J Natl Cancer Inst. 2013;105(11):1214–22. PMID: 23633265.

58. Agravani I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168(3):250–60. PMID: 18536666.

59. Islam MM, Poly TN, Walther BA, Yang HC, Jack L, Yi C. Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies. Cancers (Basel). 2020;12(3):671. PMID: 32183029.

60. Cantini L, Pecci F, Hurkmans DP, Belderbos RA, Lanesic A, Copparoni C, Aerts S, Cornellis R, Dumoulin DW, Fiordiliva I, et al. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients: Eur J Cancer. 2021;144:41–9. PMID: 33336866.

61. Awanz F, Fahmy U, Badri-Eldin S, Ibrahim T, Afzali M, Al-Rabia M, Al-Farsi A, Alhakamy N, Abduallah W, Al Sadoun H, et al. The enhanced cytotoxic and pro-apoptotic effects of optimized simvastatin-loaded emulsomes on MCF-7 breast cancer cells. Pharmaceutics. 2020;12(7):597. PMID: 32604984.

62. Wang T, Seath S, Loh X, Chan C, Hartman M, Goh B, Lee S. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 2016;7(3):2532–44. PMID: 26565813.

63. Alarcon Martinez T, Zeybek N, Muftuoglu S. Evaluation of the cytotoxic and autophagic effects of atorvastatin on MCF-7 breast cancer cells. Balkan Med J. 2018;35(3):256–62. PMID: 29485098.

64. Koyuturk M, Erozso M, Altok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett. 2007;252(2):220–8. PMID: 17125918.

65. Huang SW, Chuyuan IT, Shieue C, Yu MC, Hsu YF, Hsu M. Lovastatin-mediated MCF-7 cancer cell death involves LXBP-AMPK-p38MAPK-p53-survivin signalling cascade. J Cell Mol Med. 2020;24(2):1822–36. PMID: 31821701.

66. Bai F, Yu Z, Gao X, Gong J, Fan L, Liu S. Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p. Aging. 2019;11(10):3198–219. PMID: 31138737.

67. Alzaffi M, Vatankhah M, Ostad S. Investigation of simvastatin-induced apoptosis and cell cycle arrest in cancer stem cells of MCF-7 Cancer Cells. BioMed Res Ther. 2016;12(2):275–9. PMID: 27461641.

68. Lin Z, Zhang Z, Jiang X, Kou X, Yao B, Liu H, Sun F, Ling S, Qin N, Jiang L, et al. Mevatstatin blockade of autolysosome maturation stimulates LHBS89-induced cell death in triple-negative breast cancer cells. Oncotarget. 2017;8(11):17833–48. PMID: 28147319.

69. Buranrat B, Suvannawalot W, Naowaboot S. Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncol Lett. 2017;14(6):2423–50. PMID: 29113274.

70. Castellanos-Esparza YC, Wu S, Huang L, Buquet C, Shen R, Sanchez-Gonzalez B, Garcia Latorre EA, Boyer O, Varin R, Jimenez-Zamudio LA.
et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018;52(4):1246–54. PMID: 29436616.

80. Ghosh-Choudhury N, Mandal C, Ghosh-Choudhury N, Ghosh-Choudhury G. Simvastatin induces derepression of PTEN expression via NFκappaB to inhibit breast cancer cell growth. Cell Signal. 2010;22(5):749–58. PMID: 20060890.

81. Herrero-Martín G, López-Rivas A. Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the presence of proteins. FEBs Lett. 2008;582(17):2589–94. PMID: 18582466.

82. Deng J, Zhang R, Zeng Y, Zhu Y, Wang G. Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells. Cancer Manag Res. 2019;11:7231–42. PMID: 31839714.

83. Alqudah M, Mansour H, Mhaidat N. Simvastatin enhances innontecan-induced apoptosis in prostate cancer via inhibition of MCL-1. Saudi Pharm J. 2018;26(2):191–7. PMID: 30166915.

84. Chen B, Zhang M, Xing D, Feng Y. Atorvastatin enhances radiosensitivity in hypoxia-induced prostate cancer cells related with HIF-1α inhibition. Biosci Rep. 2017;37(4):BRS20170730. PMID: 28760843.

85. Wang Z, Zhang L, Wan Z, He Y, Huang H, Xiang H, Wu X, Zhang K, Liu Y, Goodin S, et al. Synergistic promoting effects of pentoxifylline and simvastatin on cell apoptosis, migration, invasion and tumorspheres of prostate cancer cells. Pathol Oncol Res. 2020;26(1):209–16. PMID: 29796873.

86. Brown M, Hart C, Tawadros T, Ramani V, Sangar V, Lau M, Clarke N. The apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Cancer. 2008;123(1):86–91. PMID: 18510746.

87. Toepfer N, Childress C, Parikh A, Rukstalis D, Yang W. Atorvastatin promotes p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017;8(2):e2626. PMID: 28230855.

88. Wang S, Ho H, Lin J, Shieu J, Wu C. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017;8(2):e2626. PMID: 28230855.

89. You H, Zhang W, Xie Z, Zheng Z, Zhu H, Jiang F. Pitavastatin suppressed liver cancer cells in vitro and in vivo. Onco Targets Ther. 2016;9:5383–8. PMID: 27621652.

90. Xia K, Zhang P, Hu J, Hou H, Xiong M, Xiong J, Yan N. Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells. Oncol Lett. 2018;15(4):4344–50. PMID: 29541202.

91. Liu H, Liang S, Kumar S, Weyman C, Liu W, Zhou A. Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol. 2009;63(6):997–1005. PMID: 18766339.

92. Polívka S, Rychářová Y, Kashima H, Wu R, Jung L, Kuan J, Gu J, Yuan J, Sokol L, Visvanathan K, Shih L, et al. Mevalonate pathway antagonist suppresses formation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models. Clin Cancer Res. 2015;21(20):4652–62. PMID: 26109099.

93. Otahal A, Aydemir D, Tornasch E, Minichsdorfer C. Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NCLC) lines. Sci Rep. 2020;10(1):959. PMID: 31969600.

94. Khanzada U, Pardo O, Meier C, Downward J, Seckl M, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene. 2006;25(6):877–87. PMID: 16170339.

95. Liu H, Wang Z, Li Y, Li W, Chen Y. Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo. Neoplasma. 2013;60(3):240–6. PMID: 23373992.

96. Galland S, Martin P, Fregni G, Letovacene I, Stamenkovic I. Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins. Cancer Lett. 2020;484:50–64. PMID: 32481888.

97. Shen L, Zhang Z, Lu H, Li J, Zhang S, Qi X, Zheng L, Lee K, Kim D, Kim C, Cai D, Wu Z, Qin J, Yu Y, Kim S. HMCoA-reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 2013;4:e518. PMID: 23449454.

98. Song X, Liu BC, Lu XY, Yang LL, Zhai YJ, Eaton AF, Thai TL, Eaton DC, Ma HP, Shen ZB. Lovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expression. Biochim Biophys Acta. 2014;1843(5):894–901. PMID: 24518247.

99. Sheikhholeslami K, Ali Sher A, Lockman S, Kroft D, Ganjibakhsh M, Nejati-Koshki K, Shojaei S, Ghavami S, Rastegar M, Nejati-Koshki K, Shojaei S, Ghavami S, Rastegar M. Simvastatin induces apoptosis in medulloblastoma brain tumor cells via mevalonate cascade prenylation substrates. Cancers. 2019;11(7):994. PMID: 31319483.

100. Shojaei S, Koleini N, Samiei E, Aghaei M, Cole LK, Alizadeh J, Islam MI, Vosoughi AR, Albokashy M, Butterfield Y, et al. Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. FEBS J. 2020;287(5):1005–34. PMID: 31545550.

101. Ivanov V, Hei T. Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011;16(12):1268–84. PMID: 21910007.

102. Al-Qatairi A, Alwaini S. Combined pitavastatin and dacarbazine treatment activates apoptosis and autophagy resulting in synergistic cytotoxicity in melanoma cells. Oncol Lett. 2017;14(6):7993–9. PMID: 28944246.

103. Shellman Y, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris D, Dellavalle R. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 2005;15(2):83–9. PMID: 15846140.
117. Ogunwobi O, Beales I. Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103(8):825–37. PMID: 18377146.

118. Lee J, Hong E, Jang J, Park S, Koh D, Choi M, Jang H, Kae S. Simvastatin induces apoptosis and suppresses insulin-like growth factor 1 receptor in bile duct cancer cells. Gut Liver. 2016;10(2):310–7. PMID: 26470769.

119. Miller T, Yang F, Wise CE, Meng F, Priester S, Munshi MK, Guerrier M, Yen C, Chen J, Chang Y, Hsu Y, Chiu P, Shiue C, Chuang Y, Ou G, Hsu Peng Y, He G, Tang D, Xiong L, Wen Y, Miao X, Hong Z, Yao H, Chen

120. Jang J, Lee J, Jang J, Jung C, Park S. Anti-leukemic effects of simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019;154(2):432–40. PMID: 31178149.

121. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. PMID: 21376230.

122. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30. PMID: 19678280.

123. Gobel A, Rauner M, Hoffbauer LC, Rachner TD. Cholesterol and beyond - the role of the mevalonate pathway in cancer biology. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188351. PMID: 32070596.

124. Juarez D, Fruman DA. Targeting the mevalonate pathway in cancer. Trends Cancer. 2021;7(6):52–55. PMID: 33581111.

125. Jeong A, Suazo KF, Wood WG, Distefano MD, Li LL. Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease. Crit Rev Biochem Mol Biol. 2018;53(3):279–310. PMID: 29718780.

126. Zhang Y, Liu Y, Duan J, Wang H, Zhang Y, Qiao K, Wang J. Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. Cell Cycle (Georgetown, Tex). 2019;18(23):3337–50. PMID: 31599189.

127. Kim J, Turbiv J, Rosales R, Thaete L, Rodriguez G. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019;154(2):432–40. PMID: 31178149.

128. Jang J, Lee J, Jang J, Jung C, Park S. Anti-leukemic effects of simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019;154(2):432–40. PMID: 31178149.

129. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30. PMID: 19678280.

130. Gobel A, Rauner M, Hoffbauer LC, Rachner TD. Cholesterol and beyond - the role of the mevalonate pathway in cancer biology. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188351. PMID: 32070596.

131. Juarez D, Fruman DA. Targeting the mevalonate pathway in cancer. Trends Cancer. 2021;7(6):52–55. PMID: 33581111.

132. Hagiwara N, Watanabe M, Iizuka-Ohashi M, Yokota I, Toriyama S, Sukeno K, Fukuchi Y, Matsuo K, Muto A, Saya H, et al. Simvastatin-induced angiogenic factors in mouse osteosarcoma. Cytokine. 2011;54(1):100–7. PMID: 21392498.

133. Zhang Y, Liu Y, Duan J, Wang H, Zhang Y, Qiao K, Wang J. Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. Cell Cycle (Georgetown, Tex). 2019;18(23):3337–50. PMID: 31599189.

134. Kim J, Turbiv J, Rosales R, Thaete L, Rodriguez G. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019;154(2):432–40. PMID: 31178149.

135. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. PMID: 21376230.

136. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30. PMID: 19678280.

137. Göbel A, Rauner M, Hofbauer LC, Rachner TD. Cholesterol and beyond - the role of the mevalonate pathway in cancer biology. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188351. PMID: 32070596.
apoptosis in medulloblastoma brain tumor cells via mevalonate cascade prenylation substrates. Cancers (Basel). 2019;11(7):994. PMID: 31319483.

159. Zhiu Y, Casey PJ, Kumar AP, Pervaiz S. Deciphering the signaling network works underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis. 2013;4(4):e658. PMID: 23559002.

160. Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involving in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001;22(8):1139–46. PMID: 11470741.

161. Kubatsa P, Kružliak P, Rotnek V, Jelínkova S, Mladosiovicova B. Statins in oncological research: from experimental studies to clinical practice. Crit Rev Oncol Hematol. 2014;92(3):296–311. PMID: 25226058.

162. Li M, Min W, Wang J, Wang L, Li Y, Zhou N, Yang Z, Qian Q. Effects of Helbig G, Holowiecki J. Ras signaling pathway as a target for farnesyl-prenyltransferase inhibitors–a new, promising prospects in the treatment for malignant disorders. Wiad. Lek. 2004;57(9–10):462–7. PMID: 15765763.

163. Hu T, Shen H, Huang H, Yang Z, Zhou Y, Zhao G. Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling. Anticancer Drugs. 2020;31(4):377–84. PMID: 32011362.

164. Alizadeh J, Zeki AA, Mirzaei N, Tewary S, Rezaee Moghadam A, Glogovska A, Nagakannan P, Eftekharpour E, Wiechee E, Gordon JW, et al. Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Sci Rep. 2017;7:44841. PMID: 28344327.

165. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis pathway via depletion of isoprenoids in tumor cells. Cancers (Basel). 2019;11(7):994. PMID: 31319483.

166. Feng X, Guo Y, Li S, Wang Y, Jiao Z, Cai H, Long Y, Sirka OK, Padmanaban V, Ewald AJ, Devreotes PN. Statin-induced GGPP depletion blocks macropinocytosis in human prostate cancer cells. J Biol Chem. 2020;10:499. PMID: 32318352.

167. Kusama T, Muki A, Iwaski T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 2001;61(12):4885–91. PMID: 11406567.

168. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther. 2003;2(10):941–8. PMID: 14578459.

169. White CR. On the occurrence of crystals in tumours. J Pathol Bacteriol. 1900;13(1):3–10.

170. Dessel S, Batetta B, Pulisci D, Spano O, Anchisi C, Tessitore L, Costelli P, Baccino FM, Aracioso E, Pani P. Cholesterol content in tumor tissues is inversely associated with high-density lipoprotein cholesterol in serum in patients with gastrointestinal cancer. Cancer. 1994;73(2):253–8. PMID: 8293385.

171. Kolanjiappan K, Ramachandran CR, Manoharan S. Biochemical changes in tumor tissues of oral cancer patients. Clin Biochem. 2003;36(1):61–5. PMID: 12554062.

172. Guedean N, Favre G, Hacem M, Marek E, Le Gaillard F, Soula G. Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549. Biochimme. 1993;75(9):811–9. PMID: 8274533.

173. Lum DF, McQuaid KR, Gilbertson VL, Hughes-Fulford M. Coordinate up-regulation of low-density lipoprotein receptor and cyclooxygenase-2 gene expression in human colorectal and in colorectal adenocarcinoma biopsies. Int J Cancer. 1999;83(2):162–6. PMID: 10471521.

174. Yen CF, Kaluntia CI, Chen FS, Kaprein JS, Lin CK, Lai PM. Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt's lymphoma cells. Biochim Biophys Acta. 1995;1257(1):47–57. PMID: 7599180.

175. Tditis L, Gruber A, Vitosi S. Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. J Lipid Res. 1997;38(12):2436–45. PMID: 9458267.

176. Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer. 2001;91(1):41–5. PMID: 11149418.

177. Vitosi S, Ghartoon A, Ost A, Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood. 1994;83(5):1186–93. PMID: 8294298.

178. Rudling MJ, Stähle L, Pettersson CO, Skog O. Content of low density lipoprotein receptors in breast cancer tissue related to survival of patients. Br Med J (Clin Res Ed). 1986;292(6520):580–2. PMID: 3081176.

179. Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10(3):205–12. PMID: 20147092.

180. Likus W, Siemianowicz K, Bierk K, Pakula M, Pathak H, Dutta C, Wang Q, Shojaei S, Aasraf YG, Ghavami S, et al. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Drug Resist Updat. 2016;25:13–25. PMID: 27155373.

181. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31. PMID: 11994399.

182. Attie AD, Seidah NG. Dual regulation of the LDL receptor–some clarity bottle to Scap’s MELADL. J Lipid Res. 2009;50 Suppl:S15–27. PMID: 19187573.

183. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003;144(9):3852–9. PMID: 12935658.

184. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31. PMID: 11994399.

185. Attie AD, Seidah NG. Dual regulation of the LDL receptor–some clarity and new questions. Cell Metab. 2005;1(5):290–2. PMID: 16054075.

186. Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer’s bottle to Scap’s MELADL. J Lipid Res. 2009;50 Suppl(Suppl):515–27. PMID: 18974038.

187. Simons K, Ikonen E. How cells handle cholesterol. Science. 2000;290(5497):1721–6. PMID: 11094005.
196. Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol Cancer. 2018;17(1):158. PMID: 30447690.

197. Bae JY, Lee SW, Shin YH, Lee JH, Jahng JW, Park K. P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer. Oncotarget. 2017;8(30):48972–82. PMID: 28430665.

198. Du Q, Wang G, Fan H, Wang J, Liu X, Wang H, Yang H, Yu R. Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome. Biochemical Pharmacol. 2016;105:42–54. PMID: 26921636.

199. Weichand B, Popp R, Dziumbla S, Mora J, Strack E, Elwakeel E, Frank AC, Scholich K, Pierre S, Syed SN, et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β. J Exp Med. 2017;214(9):2695–713. PMID: 28739604.

200. Mok EHK, Lee TKW. The pivotal role of the dysregulation of cholesterol homeostasis in cancer: implications for therapeutic targets. Cancers (Basel). 2020;12(6):1410. PMID: 32486083.

201. Chang TY, Li BL, Chang CC, Urano Y. Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297(1):E1–9. PMID: 19141679.

202. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim SH. Identification of SOAT1 suppresses glioblastoma growth via blocking sRBEPP1-mediated lipogenesis. Clin Cancer Res. 2016;22(21):5337–48. PMID: 27281560.

203. Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, Xing B, Sun W, Ren L, Hu B, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–61. PMID: 30814741.

204. Antalis CJ, Arnold T, Rasool T, Lee B, Buhmann K, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat. 2010;123(1):661–70. PMID: 19851860.

205. Sanoa P, Trudel D, Kron K, Dimitromanolakis A, Trachtenberg J, Baparat V, van der Kwast T, Jari KA, Diamandis EP. Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. Prostate. 2014;74(4):372–80. PMID: 24311408.

206. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 1995;15(9):1766–75. PMID: 12559107.

207. Tveten K, Strøm TB, Berge KE, Leren TP. PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment. J Endocrinol. 2010;204(3):233–40. PMID: 19837721.

208. Daniil G, Zannis VI, Chroni A. Effect of apoA-I mutations in the capacity of the LDL receptor to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol. 2009;29(4):1431–8. PMID: 19295327.

209. Chang TY, Li BL, Chang CC, Urano Y. Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297(1):E1–9. PMID: 19141679.

210. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim SH. Identification of SOAT1 suppresses glioblastoma growth via blocking sRBEPP1-mediated lipogenesis. Clin Cancer Res. 2016;22(21):5337–48. PMID: 27281560.

211. Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, Xing B, Sun W, Ren L, Hu B, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–61. PMID: 30814741.

212. Antalis CJ, Arnold T, Rasool T, Lee B, Buhmann K, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat. 2010;123(1):661–70. PMID: 19851860.

213. Lorenzi I, von Eckardstein A, Radosavljevic S, Rohrer L. Lipidation of apolipoprotein A-I by ATP-binding cassette transporter (ABC) A1 generation of proprotein-convertase-subtilisin/kexin type-9 (PCSK9). Cancer Metastasis Rev. 2019;38(4):1088–92. PMID: 31029889.

214. Galluzzi L, Green DR. Autophagy-independent functions of the autophagy machinery. Cell. 2019;177(7):1682–99. PMID: 31199916.

215. Rubinstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and cancer. Nat Cell Biol. 2018;20(3):243–51. PMID: 29476153.

216. van Beek N, Knolks DJ, Reggiori F. Genetic aberrations in macroautophagy genes leading to diseases. Biochim Biophys Acta Mol Cell Res. 2018;1865(5):803–16. PMID: 29524522.

217. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401–10. PMID: 22534666.

218. Li Z, Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim SH. Identification of SOAT1 suppresses glioblastoma growth via blocking sRBEPP1-mediated lipogenesis. Clin Cancer Res. 2016;22(21):5337–48. PMID: 27281560.

219. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim SH. Identification of SOAT1 suppresses glioblastoma growth via blocking sRBEPP1-mediated lipogenesis. Clin Cancer Res. 2016;22(21):5337–48. PMID: 27281560.

220. Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim SH. Identification of SOAT1 suppresses glioblastoma growth via blocking sRBEPP1-mediated lipogenesis. Clin Cancer Res. 2016;22(21):5337–48. PMID: 27281560.
240. Yang PM, Liu YL, Lin YC, Shun CT, Wu MS, Chen CC. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010;70(19):7699–709. PMID: 20878807.

241. Asakura K, Izumi Y, Yamamoto M, Yamauchi Y, Kawar K, Serizawa et al. J Exp Clin Cancer Res. 2021;40:241.

243. Hu MB, Zhang JW, Gao JB, Qi YW, Gao Y, Xu L, Ma Y, Wei ZZ. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018;42(5):409–15. PMID: 30300062.

244. Yan Y, Xu Z, D, Qian L, Sun L, Geng Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. PMID: 26830677.

245. Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. Ferroptosis: process and function. Cell Death Differ. 2016;23(9):1369–79. PMID: 26794493.

246. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245–54. PMID: 27932073.

247. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. PMID: 22632970.

248. Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin‑CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent mechanism of regulated cell death. Cell Res. 2019;29(5):347–64. PMID: 30443743.

249. Belavgeni A, Bornstein SR, von Mässenhausen A, Tonnus W, Stumpf J, Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford T, Phang R, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688–92. PMID: 32164900.

250. Doll S, Freitas FP, Shah R, Alavandri M, da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panziolus E, Scheel CH, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693–8. PMID: 31654899.

251. Stojanov P, Cibulskis K,/helpers avatars of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther. 2018;184:13–41. PMID: 29087002.

252. Yin Y, Xu Z, D, Qian L, Sun L, Geng Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. PMID: 26830677.

253. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. PMID: 22632970.

254. Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin‑CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent mechanism of regulated cell death. Cell Res. 2019;29(5):347–64. PMID: 30443743.
Wu LM, Wu SG, Chen F, Wu Q, Wu CM, Kang CM, He X, Zhang RY, Lu ZF, Jiang MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signa Transduct Target Ther. 2020;5(1):166. PMID: 32843638.

Jin H, He Y, Zhao R, Hu Y, Tao J, Chen J, Huang Y. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics. 2019;9(1):266–78. PMID: 30662395.

Wolfe AR, Trenton NJ, Debelius BC, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, et al. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. OncoTarget. 2016;7(50):28428–92. PMID: 27756885.

Qiu GJ, Jin MZ, Dai JX, Sun W, Feng JH, Jin WL. Reprogramming of the lipid metabolism alters the tumor microenvironment and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics. 2019;9(1):266–78. PMID: 30662395.

Palazon A, Tyrakis PA, Macias D, Velica P, Rundquist H, Fitzpatrick S, Vojnovic N, Phan AT, Loman N, Hedenfalk I, et al. An HIF-1α/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell. 2017;32(5):669–86.e665. PMID: 28602395.

Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 2001;61(16):6020–4. PMID: 11507045.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughan DJ, et al. Comprehensive audio-metric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712–20. PMID: 27354478.

Knight KR, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, Dang H, Gillmeister B, Hendershot E, Kraemer DF, et al. Group-wide, prospective metric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712–20. PMID: 27354478.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughan DJ, et al. Comprehensive audio-metric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712–20. PMID: 27354478.